<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>Pituitary via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Pituitary' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=Pituitary&t=Pituitary&s=Search&f=source]]></link>
        <lastBuildDate>Sun, 21 Mar 2010 15:01:57 +0100</lastBuildDate>
        <item>
            <title>Long term outcome following repeat transsphenoidal surgery for recurrent endocrine-inactive pituitary adenomas</title>
            <link>http://www.medworm.com/index.php?rid=3360761&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft382051222v354wx%2F</link>
            <description>We present long term follow-up for a series of 81 patients who underwent repeat surgery for recurrent non-secreting
 pituitary adenomas. We analyzed data collected from all adult patients undergoing their second microsurgical transsphenoidal
 resection of a histologically proven endocrine-inactive pituitary adenoma at the University of California at San Francisco
 between January 1970 and March 2001. Data for these patients were collected by review of medical records, mail, and/or telephone
 interviews. Visual function, anterior pituitary function, and tumor control rates were analyzed for the series. Records were
 available for a total of 81 recurrent EIA patients. The median time between their initial and repeat operations was 4.1&amp;nbsp;years.
 The mean tumor size was 2.2&amp;nbsp;±&amp;nbsp;0.2...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360761</comments>
            <pubDate>Wed, 10 Mar 2010 18:28:49 +0100</pubDate>
            <guid isPermaLink="false">3360761</guid>        </item>
        <item>
            <title>Thyroid cancer is the most common cancer associated with acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=3360762&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj106018620520455%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of the study was to screen the malignancy in an acromegalic patient group and to determine whether there was any increased
 risk and the incidence of malignancy and its association with disease characteristics such as duration of disease, latency
 in diagnosis, and GH and IGF-1 levels. One hundred-five (65 female, 40 male) patients with acromegaly followed and treated
 at Cerrahpasa Medical School, Endocrinology and Metabolism outpatient clinic between 1983 and 2007 were included in this study.
 The patients were screened with colonoscopy, mammography, and thyroid and prostate ultrasonography (US). Malignancy was detected
 in 16 (15%) patients. Thyroid cancer was found in 5 patients (4.7%), breast cancer in 3 (2.8%), colon cancer in 2 (1.9%),
 lung cancer in 2 (...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3360762</comments>
            <pubDate>Wed, 10 Mar 2010 18:28:48 +0100</pubDate>
            <guid isPermaLink="false">3360762</guid>        </item>
        <item>
            <title>A modified protocol using half-dose gadolinium in dynamic 3-Tesla magnetic resonance imaging for detection of ACTH-secreting pituitary tumors</title>
            <link>http://www.medworm.com/index.php?rid=3313040&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu188613884k6044l%2F</link>
            <description>Conclusion: A half dose of dynamic resonance imaging contrast material increases the sensitivity of
 MRI detection of ACTH-secreting pituitary tumors.
 
 
	Content Type Journal ArticleDOI 10.1007/s11102-010-0222-yAuthors
		Lesly Portocarrero-Ortiz, Instituto Nacional de Neurologia y Neurocirugia “Manuel Velasco Suarez” Department of Endocrinology Insurgentes Sur 3877 Col. La Fama Mexico City 14269 MexicoDulce Bonifacio-Delgadillo, Instituto Nacional de Neurologia y Neurocirugia “Manuel Velasco Suarez” Department of Neuroradiology Insurgentes Sur 3877 Col. La Fama Mexico City 14269 MexicoArturo Sotomayor-González, Instituto Nacional de Neurologia y Neurocirugia “Manuel Velasco Suarez” Department of Neurosurgery Insurgentes Sur 3877 Col. La Fama Mexico City 14269 MexicoArturo Ga...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3313040</comments>
            <pubDate>Thu, 25 Feb 2010 08:00:45 +0100</pubDate>
            <guid isPermaLink="false">3313040</guid>        </item>
        <item>
            <title>Effects of metformin administration on plasma gonadotropin levels in women with infertility, with an in vitro study of the direct effects on the pituitary gonadotrophs</title>
            <link>http://www.medworm.com/index.php?rid=3308543&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk3114u65v5774v28%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Changes in LH and FSH levels were evaluated before and after metformin administration. In all 25 patients, plasma LH levels
 were significantly reduced after 3&amp;nbsp;months of metformin administration (500–1,500&amp;nbsp;mg/day). When patients were classified into
 a PCOS group (n&amp;nbsp;=&amp;nbsp;12) or a non-PCOS group (n&amp;nbsp;=&amp;nbsp;13), the reduction in LH levels only remained significant in the PCOS group. Plasma FSH levels were unchanged following
 metformin treatment when all patients were considered collectively and when patients were classified based on PCOS. LH/FSH
 ratio was significantly reduced only in the PCOS group. To examine the direct effect of metformin on gonadotropin-secreting
 cells, gonadotroph cell line, LβT2 was used for in vitro studies. Treatment of ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3308543</comments>
            <pubDate>Wed, 24 Feb 2010 06:54:39 +0100</pubDate>
            <guid isPermaLink="false">3308543</guid>        </item>
        <item>
            <title>Carotid artery visualization during anterior skull base surgery: a novel protocol for neuronavigation</title>
            <link>http://www.medworm.com/index.php?rid=3270478&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa18664549600463n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Detailed knowledge of the vascular anatomy of the anterior skull base is critical to successful surgery in this area. Whereas
 conventional neuronavigational approaches combine MRI (± contrast) for tumor visualization and CT (± C) for bony and vascular
 anatomy, we describe the Canadian and Austrian experiences using a novel protocol integrating MR angiography (MRA) into surgical
 neuronavigation to provide superior visualization of the carotid arteries. The pre-operative imaging protocol employs a T1-weighted,
 3D fast spoiled gradient echo MRI (± C) for soft tissue anatomy, a plain CT for bony anatomy, and a 3D time-of-flight MR angiography
 for carotid anatomy. The series are imported into the Medtronic StealthStation® TREON® Treatment Guidance System; during in...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270478</comments>
            <pubDate>Fri, 12 Feb 2010 07:18:06 +0100</pubDate>
            <guid isPermaLink="false">3270478</guid>        </item>
        <item>
            <title>Primary pituitary lymphoma in immunocompetent patient: diagnostic problems and prolonged follow-up</title>
            <link>http://www.medworm.com/index.php?rid=3264221&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg10576107700n048%2F</link>
            <description>The objective of this report is to
 report a low-grade primary pituitary lymphoma, diagnostic problems and to give more evidence about the evolution of this rare
 disease. A 49 y.o. woman was referred to our clinic with symptoms of hypopituitarism. A diagnostic work-up showed mild anemia,
 an erythrocyte sedimentation rate of 122&amp;nbsp;mm/h and a negative Elisa test for HIV. Panhypopituitarism was confirmed and the
 MRI showed a 20&amp;nbsp;mm sellar and suprasellar enhancing mass with a thickening of the pituitary stalk, chiasmal compression and
 bitemporal hemianopsia. She underwent transsphenoidal resection only 10&amp;nbsp;months later for non medical reasons. During this
 period she was clinically asymptomatic on hormonal replacement therapy. A new MRI showed regression of the suprasellar exte...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3264221</comments>
            <pubDate>Tue, 09 Feb 2010 17:47:20 +0100</pubDate>
            <guid isPermaLink="false">3264221</guid>        </item>
        <item>
            <title>Adverse anthropometric risk profile in biochemically controlled acromegalic patients: comparison with an age- and gender-matched primary care population</title>
            <link>http://www.medworm.com/index.php?rid=3241248&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa1317l09j84wm322%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;GH and IGF-1 play an important role in the regulation of metabolism and body composition. In patients with uncontrolled acromegaly,
 cardiovascular morbidity and mortality are increased but are supposed to be normalised after biochemical control is achieved.
 We aimed at comparing body composition and the cardiovascular risk profile in patients with controlled acromegaly and controls.
 A cross-sectional study. We evaluated anthropometric parameters (height, weight, body mass index (BMI), waist and hip circumference,
 waist to height ratio) and, additionally, cardiovascular risk biomarkers (fasting plasma glucose, HbA1c, triglycerides, total
 cholesterol, HDL, LDL, and lipoprotein (a), in 81 acromegalic patients (58% cured) compared to 320 age- and gender-matched
 contro...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3241248</comments>
            <pubDate>Wed, 03 Feb 2010 17:59:45 +0100</pubDate>
            <guid isPermaLink="false">3241248</guid>        </item>
        <item>
            <title>Management of prolactinomas in Brazil: an electronic survey</title>
            <link>http://www.medworm.com/index.php?rid=3224028&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqh44k7t072t1l6x0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Dopamine agonists are the treatment of choice for prolactinomas. However, there are still controversies concerning dose, treatment
 duration and criteria for drug withdrawal in different clinical situations. The aim of this study was to assess diagnostic
 and therapeutic approaches to prolactinomas among members of the Brazilian Society of Endocrinology and Metabolism (SBEM).
 SBEM members answered a questionnaire sent by e-mail that included 18 questions related to controversial issues about the
 management of prolactinomas. Among SBEM members, 721 (approximately 24% of total) answered the questionnaire. Concerning the
 diagnosis, 38% of the respondents stated that prolactin levels&amp;nbsp;&amp;lt;&amp;nbsp;100&amp;nbsp;ng/ml would exclude the presence of a prolactinoma. Most
 of the...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224028</comments>
            <pubDate>Wed, 27 Jan 2010 19:58:12 +0100</pubDate>
            <guid isPermaLink="false">3224028</guid>        </item>
        <item>
            <title>Effect of transsphenoidal surgery on decreased visual acuity caused by pituitary apoplexy</title>
            <link>http://www.medworm.com/index.php?rid=3154553&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgv214n38l64u104w%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We treated 12 patients with pituitary apoplexy out of 103 patients with pituitary tumors from August 1994 to March 2008 in
 the Nishi-Kobe Medical Center. The male to female ratio was 1:2 and the average age was 43&amp;nbsp;years old, ranging from 19 to 73.
 The symptoms on presentation were a decrease of visual acuity in nine, headache in seven, endocrinological disturbance in
 six, visual field defect in seven, a febrile state in six, vomiting in four, oculomotor disturbance in two, abducens palsy
 in one, and transient altered consciousness in one. All patients underwent transsphenoidal surgery and, in four of these,
 surgery was conducted within 7&amp;nbsp;days after onset. All nine patients with a decrease in the visual acuity recovered (100%) and,
 in addition, complete o...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3154553</comments>
            <pubDate>Tue, 05 Jan 2010 17:02:34 +0100</pubDate>
            <guid isPermaLink="false">3154553</guid>        </item>
        <item>
            <title>Pituitary function in subjects with mild traumatic brain injury: a review of literature and proposal of a screening strategy</title>
            <link>http://www.medworm.com/index.php?rid=3125377&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1u3526h77m763146%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Traumatic brain injury (TBI) is an important public health problem all over the world. The level of consciousness of the patients
 and the severity of the brain injury is commonly evaluated by the Glascow Coma Scale as mild, moderate and severe TBI. When
 we consider the high frequency of mild TBI (MTBI) among the all TBI patients the burden of the pituitary dysfunction problem
 in this group could not be ignored. However, one of the most important and still unresolved questions is which patients with
 MTBI should be screened for hypopituitarism? Another type of head trauma which could be considered as the subgroup of MTBI
 is sports related chronic repetitive head trauma. Therefore, in this review we will discuss the frequency, characteristics
 and current management o...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3125377</comments>
            <pubDate>Sat, 26 Dec 2009 16:39:23 +0100</pubDate>
            <guid isPermaLink="false">3125377</guid>        </item>
        <item>
            <title>The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome</title>
            <link>http://www.medworm.com/index.php?rid=3090724&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq786g22m7j002671%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The Endocrine Tumor Summit convened in December 2008 to address 6 statements prepared by panel members that reflect important
 questions in the treatment of acromegaly and carcinoid syndrome. Data pertinent to each of the statements were identified
 through review of pertinent literature by one of the 9-member panel, enabling a critical evaluation of the statements and
 the evidence supporting or refuting them. Three statements addressed the validity of serum growth hormone (GH) and insulin-like
 growth factor-I (IGF-I) concentrations as indicators or predictors of disease in acromegaly. Statements regarding the effects
 of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoid
 syndrome, and the ef...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3090724</comments>
            <pubDate>Sun, 13 Dec 2009 06:43:05 +0100</pubDate>
            <guid isPermaLink="false">3090724</guid>        </item>
        <item>
            <title>The risk for breast cancer is not evidently increased in women with hyperprolactinemia</title>
            <link>http://www.medworm.com/index.php?rid=3090725&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F040u32306201m3v0%2F</link>
            <description>In conclusion, there is no clear evidence for increased breast
 cancer risk in female patients treated for either idiopathic hyperprolactinemia or prolactinomas. The uncertainty about the
 exact risk that is due to the relatively low number of breast cancer cases, should be overcome by pooling results in a future
 meta-analysis.
 
	Content Type Journal ArticleDOI 10.1007/s11102-009-0214-yAuthors
		O. M. Dekkers, Leiden University Medical Center Department of Endocrinology and Metabolic Diseases P.O. Box 9600 2300 RC Leiden The NetherlandsJ. A. Romijn, Leiden University Medical Center Department of Endocrinology and Metabolic Diseases P.O. Box 9600 2300 RC Leiden The NetherlandsA. de Boer, Utrecht University Division of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmac...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3090725</comments>
            <pubDate>Sat, 12 Dec 2009 14:19:36 +0100</pubDate>
            <guid isPermaLink="false">3090725</guid>        </item>
        <item>
            <title>A heritable predisposition to pituitary tumors</title>
            <link>http://www.medworm.com/index.php?rid=3090726&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff5577727u470171l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pituitary tumors are prevalent in the general population, with a frequency of nearly 1 in 5. The cause of most pituitary tumors
 remains unknown, although a genetic contribution is recognized for some. We analyzed the Utah Population Data Base (UPDB),
 a resource combining a computerized genealogy of the Utah population with a statewide tumor registry, to investigate familial
 clustering of pituitary tumors. We analyzed the genetic relationships among 741 individuals diagnosed with benign or malignant
 pituitary tumors who had Utah genealogy data. To test for evidence of genetic contribution to predisposition, we compared
 average relatedness between all pairs of individuals with pituitary tumors with the expected relatedness in this population.
 We also estimated relat...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3090726</comments>
            <pubDate>Sat, 12 Dec 2009 14:19:35 +0100</pubDate>
            <guid isPermaLink="false">3090726</guid>        </item>
        <item>
            <title>Evaluation of antioxidant systems in pituitary-adrenal axis diseases</title>
            <link>http://www.medworm.com/index.php?rid=3090727&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx342472435h55060%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The role of adrenal steroids in antioxidant regulation is not known. Previously, we demonstrated some Coenzyme Q10 (CoQ10) alterations in pituitary diseases, which can induce complex pictures due to alterations of different endocrine axes. Therefore
 we determined CoQ10 and Total Antioxidant Capacity (TAC) in pituitary-dependent adrenal diseases: 6 subjects with ACTH-dependent adrenal hyperplasia
 (AH); 19 with secondary isolated hypoadrenalism (IH), 19 with associated hypothyroidism (multiple pituitary deficiencies,
 MPH). CoQ10 was assayed by HPLC; TAC by the system metmyoglobin-H2O2, which, interacting with the chromogenous 2,2I-azinobis-(3-ethylbenzothiazoline-6-sulphonate), generates a spectroscopically revealed radical compound after a latency time
 (Lag) proporti...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3090727</comments>
            <pubDate>Sat, 12 Dec 2009 14:19:34 +0100</pubDate>
            <guid isPermaLink="false">3090727</guid>        </item>
        <item>
            <title>Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor</title>
            <link>http://www.medworm.com/index.php?rid=3064571&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa86m2w3q820102q0%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Only rarely do corticotroph pituitary tumors become invasive leading to symptoms caused by compression of cranial nerves and
 other local structures. When aggressive pituitary neuroendocrine tumors do develop, conventional treatment options are of
 limited success. A 50-year-old man developed a giant invasive corticotroph pituitary tumor 2&amp;nbsp;years after initial presentation.
 His tumor and symptoms failed to respond to maximal surgical, radio-surgical, radiation and medical therapy and a bilateral
 adrenalectomy was done. He subsequently developed rapid growth of his tumor leading to multiple cranial nerve deficits. He
 was administered salvage chemotherapy with capecitabine and temozolomide (CAPTEM), a novel oral chemotherapy regimen developed
 at our institution fo...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3064571</comments>
            <pubDate>Thu, 03 Dec 2009 18:23:18 +0100</pubDate>
            <guid isPermaLink="false">3064571</guid>        </item>
        <item>
            <title>Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease</title>
            <link>http://www.medworm.com/index.php?rid=3041297&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4m17t88p17424162%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The expression of dopamine receptor subtypes has been reported in corticotroph adenomas, and this finding support the possibility
 for medical treatment of Cushing’s disease (CD) with dopamine agonists when conventional treatment has failed. The aim of
 this study was to evaluate the effectiveness of cabergoline (at doses of up 3&amp;nbsp;mg/week), alone or combined with relatively
 low doses of ketoconazole (up to 400&amp;nbsp;mg/day), in 12 patients with CD unsuccessfully treated by transsphenoidal surgery. After
 6&amp;nbsp;months of cabergoline therapy, normalization of 24&amp;nbsp;h urinary free cortisol (UFC) levels occurred in three patients (25%) at doses ranging from 2–3&amp;nbsp;mg/week,
 whereas reductions ranging from 15.0 to 48.4% were found in the remaining. The addition ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3041297</comments>
            <pubDate>Fri, 27 Nov 2009 07:07:04 +0100</pubDate>
            <guid isPermaLink="false">3041297</guid>        </item>
        <item>
            <title>Diagnostic value of 18F-dihydroxyphenylalanine positron emission tomography for growth hormone-producing pituitary adenoma</title>
            <link>http://www.medworm.com/index.php?rid=2993206&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3157240q1703381v%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s11102-009-0208-9Authors
		Takafumi Taguchi, Kochi University Kochi Medical School Kohasu, Oko-cho Nankoku JapanToshihiro Takao, Kochi University Kochi Medical School Kohasu, Oko-cho Nankoku JapanYasumasa Iwasaki, Kochi University Kochi Medical School Kohasu, Oko-cho Nankoku JapanKenichi Oyama, Toranomon Hospital Department of Hypothalamic &amp; Pituitary Surgery Minato-ku Tokyo JapanShozo Yamada, Toranomon Hospital Department of Hypothalamic &amp; Pituitary Surgery Minato-ku Tokyo JapanMari Inoue, Kochi University Kochi Medical School Kohasu, Oko-cho Nankoku JapanYoshio Terada, Kochi University Kochi Medical School Kohasu, Oko-cho Nankoku Japan
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2993206</comments>
            <pubDate>Fri, 13 Nov 2009 18:13:12 +0100</pubDate>
            <guid isPermaLink="false">2993206</guid>        </item>
        <item>
            <title>Acromegaly with negative pituitary MRI and no evidence of ectopic source: the role of transphenoidal pituitary exploration?</title>
            <link>http://www.medworm.com/index.php?rid=2986612&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F771v2533k53v8t55%2F</link>
            <description>We report a patient with acromegaly and an unremarkable pituitary MR
 imaging who had negative work up for ectopic growth hormone-releasing hormone (GHRH) or GH secreting tumors. Transsphenoidal
 pituitary exploration revealed a pituitary adenoma located on the left side of the sella against the medial wall of the cavernous
 sinus extending posteriorly along the floor of the sella all the way to the right side. The acromegaly was treated with resection
 of the pituitary adenoma and normalization of serum insulin-like growth factor 1 (IGF-1) and GH levels. In a patient with
 acromegaly and unremarkable pituitary MR imaging, with no evidence of ectopic GH and GHRH production, transsphenoidal pituitary
 exploration is a reasonable approach and may result in clinical improvement and biochemica...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2986612</comments>
            <pubDate>Tue, 10 Nov 2009 18:58:08 +0100</pubDate>
            <guid isPermaLink="false">2986612</guid>        </item>
        <item>
            <title>Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naïve patients with acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=2975093&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu3rl812148534417%2F</link>
            <description>This study assessed the efficacy and safety of self- or partner-administration of lanreotide
 in patients with acromegaly. This was a six-month, single-arm, open-label study conducted at 13 endocrinology clinics. Fifty-nine
 patients received deep subcutaneous lanreotide injections every 28&amp;nbsp;days. Twelve patients started on 120&amp;nbsp;mg lanreotide and
 forty-seven started on 90&amp;nbsp;mg lanreotide. At week 16, the dose was adjusted to 60, 90 or 120&amp;nbsp;mg based on insulin-like growth
 factor-1 (IGF-1) levels at week 12. Fifty-nine patients with acromegaly either switched from long-acting octreotide (switch;
 n&amp;nbsp;=&amp;nbsp;33) or were somatostatin analogue treatment-naïve or not currently taking long-acting octreotide (“other”; n&amp;nbsp;=&amp;nbsp;26). The key endpoints included the perce...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2975093</comments>
            <pubDate>Sat, 07 Nov 2009 19:14:37 +0100</pubDate>
            <guid isPermaLink="false">2975093</guid>        </item>
        <item>
            <title>Management of acromegaly in Latin America: expert panel recommendations</title>
            <link>http://www.medworm.com/index.php?rid=2956312&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0g162x60256327l5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although there are international guidelines orienting physicians on how to manage patients with acromegaly, such guidelines
 should be adapted for use in distinct regions of the world. A panel of neuroendocrinologists convened in Mexico City in August
 of 2007 to discuss specific considerations in Latin America. Of major discussion was the laboratory evaluation of acromegaly,
 which requires the use of appropriate tests and the adoption of local institutional standards. As a general rule to ensure
 diagnosis, the patient’s GH level during an oral glucose tolerance test and IGF-1 level should be evaluated. Furthermore,
 to guide treatment decisions, both GH and IGF-1 assessments are required. The treatment of patients with acromegaly in Latin
 America is influenced by ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2956312</comments>
            <pubDate>Fri, 30 Oct 2009 18:25:03 +0100</pubDate>
            <guid isPermaLink="false">2956312</guid>        </item>
        <item>
            <title>Hypopituitarism due to sports related head trauma and the effects of growth hormone replacement in retired amateur boxers</title>
            <link>http://www.medworm.com/index.php?rid=2921728&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F35824g56318m7958%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Traumatic brain injury (TBI) has been recently recognized as a leading cause of pituitary dysfunction. Current data clearly
 demonstrated that sports related head trauma due to boxing, kickboxing, and soccer might results in pituitary hormone deficiencies,
 isolated growth hormone (GH) deficiency in particular. In the present report physiologic dose GH replacement therapy (GHRT)
 was performed in two GH deficient retired amateur boxers for the first time. The boxers received recombinant GH for 6&amp;nbsp;months.
 After 6&amp;nbsp;months of GHRT there were substantial improvements, but not complete normalization, in the body composition parameters,
 lipid profiles and quality of life scores in both boxers. These preliminary results suggest that GHRT may have beneficial
 effects ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2921728</comments>
            <pubDate>Thu, 22 Oct 2009 06:06:57 +0100</pubDate>
            <guid isPermaLink="false">2921728</guid>        </item>
        <item>
            <title>Apoplexy in non functioning pituitary adenoma after one dose of leuprolide as treatment for prostate cancer</title>
            <link>http://www.medworm.com/index.php?rid=2913885&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd1wgw58uk037j123%2F</link>
            <description>We report the case of a 60&amp;nbsp;year old male who complained of headache and blurry vision—that progressed to left ophthalmoplegia
 and ptosis—after receiving a dose of leuprolide for Prostate cancer therapy. Imaging showed a hemorrhagic sellar mass. The
 patient underwent transsphenoidal debulking, and the tissue obtained demonstrated immunohistochemical staining for LH. A literature
 review revealed nine previously reported cases of pituitary apoplexy after GnRH agonist therapy for prostate cancer. In most
 cases, the sellar tissues stained for LH, consistent with a gonadotropinoma. The pathophysiology of these events is unclear,
 but recent animal models suggest possible explanations. The predominance of gonadotropinomas is important because they do
 not usually present with hyperse...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2913885</comments>
            <pubDate>Tue, 20 Oct 2009 16:20:48 +0100</pubDate>
            <guid isPermaLink="false">2913885</guid>        </item>
        <item>
            <title>Outcome of gonadotropin therapy for male infertility due to hypogonadotrophic hypogonadism</title>
            <link>http://www.medworm.com/index.php?rid=2906261&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fpp008q4v08445682%2F</link>
            <description>We report our extensive
 experience with intramuscular injections of gonadotropins, one of the two methods used for this purpose. Eighty-seven married
 men (median age, 28&amp;nbsp;years) with either congenital (47 men) or acquired (40 men) HH were treated for a median of 26&amp;nbsp;months
 (range, 6–57) with intramuscular injections of gonadotropins (HCG/HMG) three times weekly for the purpose of achieving fertility.
 The outcome was assessed by achievement of one or more pregnancies. Of the 151 courses of HCG/HMG treatment administered to
 87 patients, 85 courses (56.3%) were successful, resulting in 85 pregnancies (median pregnancy rate 2, range 1–10) in 35 patients
 (40%) while 52 cases did not achieve pregnancy. Responders had larger pretherapy testicular volume (9&amp;nbsp;±&amp;nbsp;3.6&amp;nbsp;...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2906261</comments>
            <pubDate>Fri, 16 Oct 2009 17:59:17 +0100</pubDate>
            <guid isPermaLink="false">2906261</guid>        </item>
        <item>
            <title>Cushing disease as possible cause of persistent growth failure despite growth hormone therapy in a small for gestational age male</title>
            <link>http://www.medworm.com/index.php?rid=2826089&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb5131788870t8083%2F</link>
            <description>We report the case of an 11-year-old Caucasian male who developed early adrenarche, hypertension and insulin resistance
 on GH therapy for SGA and profound short stature (ht −5 SD). This patient demonstrated a poor response to GH therapy and developed
 physical and biochemical findings of insulin resistance responsive to metformin therapy. He remained hypertensive, however,
 and continued to have elevated serum dehydroepiandrosterone sulfate levels. Urinary free cortisol excretion was subsequently
 found to be elevated. The diagnosis of Cushing’s disease was confirmed with inferior petrosal sinus sampling and pituitary
 MRI. The patient underwent partial adenohypophysectomy with resulting normalization of plasma cortisol levels and associated
 symptoms. Our patient’s diagnosis of Cus...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2826089</comments>
            <pubDate>Mon, 21 Sep 2009 16:21:12 +0100</pubDate>
            <guid isPermaLink="false">2826089</guid>        </item>
        <item>
            <title>Inferior petrosal sinus ACTH and prolactin responses to CRH in ACTH-dependent Cushing’s syndrome: a single centre experience from the United Kingdom</title>
            <link>http://www.medworm.com/index.php?rid=2816197&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh4x211ll8w343310%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Inferior petrosal sinus sampling (IPSS) of ACTH with CRH stimulation helps distinguish pituitary ACTH-dependent Cushing’s
 syndrome from the ectopic ACTH syndrome (EAS). The usefulness of the paradoxical response of other pituitary hormones including
 prolactin to CRH remains controversial. Data from 33 IPSS procedures carried out at the Walton Centre for Neurology and Neurosurgery
 in Liverpool were analyzed. Patients were selected for this procedure if they had been diagnosed with ACTH dependent Cushing’s
 syndrome and the majority had no obvious pituitary adenoma on Magnetic Resonance Imaging. Satisfactory simultaneous bilateral
 catheterization was accomplished in 23/33 (success rate 70%). The diagnostic sensitivity of a basal central/peripheral ACTH
 ratio &amp;gt;...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2816197</comments>
            <pubDate>Sat, 19 Sep 2009 05:52:51 +0100</pubDate>
            <guid isPermaLink="false">2816197</guid>        </item>
        <item>
            <title>Sellar collision tumor involving pituitary gonadotroph adenoma and chondroma: a potential clinical diagnosis</title>
            <link>http://www.medworm.com/index.php?rid=2810876&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F7419l83078588824%2F</link>
            <description>We report on a 74-year-old male patient who presented with progressive neuroophthalmologic symptoms soon after the administration
 of a long-acting gonadotropin-releasing hormone agonist for treatment of a prostate cancer. Imaging revealed a destructively
 growing and extensively calcified sellar mass inconsistent with a pituitary adenoma. A transseptal transsphenoidal tumor mass
 reduction yielded a histological diagnosis of a collision tumor comprised of a gonadotroph adenoma intermingled with osteochondroma.
 We discuss a potential causal relationship between the administration of the long-acting gonadotropin-releasing hormone agonist
 and the sudden appearance of the previously unsuspected sellar lesion. Although the association of these two tumors is very
 likely coincidental, the pos...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2810876</comments>
            <pubDate>Thu, 17 Sep 2009 12:39:38 +0100</pubDate>
            <guid isPermaLink="false">2810876</guid>        </item>
        <item>
            <title>Overview of vascular complications of pituitary surgery with special emphasis on unexpected abnormality</title>
            <link>http://www.medworm.com/index.php?rid=2767321&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu4w465vlx2q82v67%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Arterial bleeding during transsphenoidal surgery for pituitary adenoma is known complication. This usually happens due to
 rupture of intracavernous carotid or delayed hemorrhage due to the carotico-cavernous fistula and/or pseudoaneurysm. There
 is also evidence that cavernous carotid aneurysms may occur with pituitary tumors, yet largest series failed to demonstrate
 any link between aneurysm formation and pituitary tumors. Usually such an aneurysm rupture results in formation of carotico-cavernous
 fistula. However, pituitary apoplexy and even epistaxis have been reported. In this paper we present a patient with recurrent
 pituitary adenoma and cavernous carotid artery aneurysm, which caused significant hemorrhage during the surgery. Although
 retrospective analysis ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2767321</comments>
            <pubDate>Thu, 03 Sep 2009 06:35:49 +0100</pubDate>
            <guid isPermaLink="false">2767321</guid>        </item>
        <item>
            <title>Diagnostic efficacy of midnight cortisol and midnight ACTH in the diagnosis and localisation of Cushing’s syndrome</title>
            <link>http://www.medworm.com/index.php?rid=2744992&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn65g27467v2w6m70%2F</link>
            <description>This study evaluated the usefulness of sleeping midnight serum cortisol (SMNC) as
 a diagnostic test for hypercortisolemia. A simultaneously done midnight plasma ACTH level was used to classify the disease
 as ACTH dependent or independent. Standard biochemical tests, SMNC, midnight plasma ACTH and appropriate imaging evaluated
 patients with a clinical suspicion of Cushing’s syndrome. We evaluated 43 patients with CS comprising of 34 patients with
 Cushing’s disease (CD), 2 patients with thymic carcinoid producing ectopic CS, 5 patients with adrenal carcinoma and 2 with
 adrenal adenoma. Thirteen patients with clinical suspicion were also evaluated with the above tests and CS was ruled out.
 SMNC, midnight plasma ACTH and dexamethasone suppressed cortisol was collected from patients w...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2744992</comments>
            <pubDate>Fri, 28 Aug 2009 15:02:20 +0100</pubDate>
            <guid isPermaLink="false">2744992</guid>        </item>
        <item>
            <title>Primary sellar lymphoma: intravascular large B-cell lymphoma diagnosed as a double cancer and improved with chemotherapy, and literature review of primary parasellar lymphoma</title>
            <link>http://www.medworm.com/index.php?rid=2735767&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Frlh60k186kr42176%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Lymphoma is one of the causative factors of hypothalamus–pituitary dysfunction, and intravascular large B-cell lymphoma (IVLBCL)
 is a subtype of primary extranodal neoplasm. A 69-year-old woman visited our hospital because of general fatigue. We diagnosed
 her with presumable non-functional primary pituitary adenoma and subsequent dysfunction. Eight months after, the patient revisited
 our hospital because of dyspnea. Though we conducted systemic investigations including chest and abdomen enhanced computer
 tomography, transbronchial lung biopsy, and bone marrow biopsy, the diagnosis was not confirmed. Inadvertently, a breast cancer
 was found, and the surgical specimen proved that the patient had double cancer—adenocarcinoma and IVLBCL. Rituximab, cyclophosphamide...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2735767</comments>
            <pubDate>Tue, 25 Aug 2009 16:58:55 +0100</pubDate>
            <guid isPermaLink="false">2735767</guid>        </item>
        <item>
            <title>Endoscopic endonasal transsphenoidal surgery: surgical results of 228 pituitary adenomas treated in a pituitary center</title>
            <link>http://www.medworm.com/index.php?rid=2723678&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj0l225185769814t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pituitary tumors are challenging tumors in the sellar region. Surgical approaches to the pituitary have undergone numerous
 refinements over the last 100&amp;nbsp;years. The introduction of the endoscope have revolutionized pituitary surgery. The aim of this
 study is to report the results of a consecutive series of patients undergoing pituitary surgery using a pure endoscopic endonasal
 approach and to evaluate the efficacy and safety of this procedure. We reviewed the data of 228 consecutive patients who underwent
 endonasal transsphenoidal adenoma removal over an 10-year period. Pre- and post-operative hormonal status (at least 3&amp;nbsp;months
 after surgery) were analyzed and compared with clinical parameters presented by the patients. Tumor removal rate, endocrinological...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2723678</comments>
            <pubDate>Thu, 20 Aug 2009 19:51:33 +0100</pubDate>
            <guid isPermaLink="false">2723678</guid>        </item>
        <item>
            <title>Possible role of a radiation-induced p53 mutation in a Nelson’s syndrome patient with a fatal outcome</title>
            <link>http://www.medworm.com/index.php?rid=2679917&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe6600651q126r437%2F</link>
            <description>In this study we report an adult male
 patient with NS who underwent both transsphenoidal and transcranial pituitary surgeries, conventional and stereotaxic radiotherapy
 and brachytherapy. Despite of the efforts to control tumor mass and growth, this macroadenoma displayed relentless growth
 and aggressive behavior. DNA extracted from the first two surgical samples, as well as DNA from peripheral blood leukocytes
 disclosed normal p53 sequence. DNA extracted from tumor samples obtained at surgeries performed after pituitary irradiation carried a somatic
 heterozygous mutation, consisting of a deletion of four cytosines between nucleotides 12,144–12,149 in exon 4 of the p53 gene. This frameshift mutation creates a stop codon in exon 4 excluding the expression of a functional protein from...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2679917</comments>
            <pubDate>Tue, 04 Aug 2009 21:55:23 +0100</pubDate>
            <guid isPermaLink="false">2679917</guid>        </item>
        <item>
            <title>Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes</title>
            <link>http://www.medworm.com/index.php?rid=2651542&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F028r767515631440%2F</link>
            <description>We describe
 the first two cases of hypopituitarism in prostate cancer subjects undergoing experimental therapy with ipilimumab. The clinical
 evidence strongly suggests that the prostate cancer subjects developed autoimmune hypophysitis as a consequence of anti-CTLA-4
 treatment. High dose glucocorticoid treatment resulted in markedly improved symptoms, and resolution of focal symptoms and
 diabetes insipidus. One subject recovered pituitary-thyroid axis function after 9&amp;nbsp;months; however, both continue to require
 GC replacement. These cases highlight the importance of early screening and treatment for hypopituitarism in all subjects
 undergoing treatment with anti-CTLA-4 therapy to prevent a potentially fatal outcome from secondary adrenal insufficiency,
 a readily treatable disease....</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2651542</comments>
            <pubDate>Tue, 28 Jul 2009 18:23:31 +0100</pubDate>
            <guid isPermaLink="false">2651542</guid>        </item>
        <item>
            <title>Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension</title>
            <link>http://www.medworm.com/index.php?rid=3098076&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff721873t275m138w%2F</link>
            <description>In conclusion, Lan-Autogel was effective
 in controlling GH and IGF-1 hypersecretion in patients with acromegaly and showed a rapid onset of action.
 
	Content Type Journal ArticleDOI 10.1007/s11102-009-0191-1Authors
		Shlomo Melmed, Cedars-Sinai Medical Center Department of Medicine Los Angeles CA USADavid Cook, Oregon Health &amp; Science University Department of Medicine Portland OR USAJochen Schopohl, Medizinische Klinik Innenstadt Division of Endocrinology Munich GermanyMiklos I. Goth, National Health Center Division of Endocrinology, 2nd Department of Medicine Budapest HungaryKaren S. L. Lam, University of Hong Kong Department of Medicine Hong Kong ChinaJosef Marek, Charles University 3rd Department of Medicine, 1st School of Medicine Prague Czech Republic
	

	
		Journal PituitaryOnline ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3098076</comments>
            <pubDate>Tue, 28 Jul 2009 18:23:29 +0100</pubDate>
            <guid isPermaLink="false">3098076</guid>        </item>
        <item>
            <title>Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension</title>
            <link>http://www.medworm.com/index.php?rid=2651543&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff721873t275m138w%2F</link>
            <description>In conclusion, Lan-Autogel was effective
 in controlling GH and IGF-1 hypersecretion in patients with acromegaly and showed a rapid onset of action.
 
	Content Type Journal ArticleDOI 10.1007/s11102-009-0191-1Authors
		Shlomo Melmed, Cedars-Sinai Medical Center Department of Medicine Los Angeles CA USADavid Cook, Oregon Health &amp; Science University Department of Medicine Portland OR USAJochen Schopohl, Medizinische Klinik Innenstadt Division of Endocrinology Munich GermanyMiklos I. Goth, National Health Center Division of Endocrinology, 2nd Department of Medicine Budapest HungaryKaren S. L. Lam, University of Hong Kong Department of Medicine Hong Kong ChinaJosef Marek, Charles University 3rd Department of Medicine, 1st School of Medicine Prague Czech Republic
	

	
		Journal PituitaryOnline ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2651543</comments>
            <pubDate>Tue, 28 Jul 2009 18:23:29 +0100</pubDate>
            <guid isPermaLink="false">2651543</guid>        </item>
        <item>
            <title>Rathke’s cleft cyst presenting as bilateral abducens nerve palsy</title>
            <link>http://www.medworm.com/index.php?rid=2638912&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F48025301r0211335%2F</link>
            <description>We present a patient with a Rathke’s cleft cyst who presented with rapidly progressive bilateral 6th nerve palsy. A 20-year-old
 woman with a history of cleft palate, hypertension, and hydronephrotic kidneys presented with a one month history of headache,
 associated with dizziness and diplopia on horizontal gaze. Examination was significant for profound bilateral 6th nerve palsies.
 Magnetic resonance imaging showed a hypodense mass that filled the sella and compressed the right cavernous sinus without
 contacting the optic chiasm. Pituitary function was normal. An endoscopic, transnasal transsphenoidal resection of the lesion
 was performed; microscopic examination revealed a Rathke’s cleft cyst. Surgical excision resulted in near complete resolution
 of the bilateral 6th nerve palsy...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2638912</comments>
            <pubDate>Thu, 23 Jul 2009 16:42:13 +0100</pubDate>
            <guid isPermaLink="false">2638912</guid>        </item>
        <item>
            <title>Collision sellar lesions: experience with eight cases and review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=2516032&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9l5j730073hl627g%2F</link>
            <description>We present a series of eight collision sellar lesions indentified among 548 transsphenoidally
 resected pituitary adenomas in two Neurosurgical Departments. The histological studies confirmed a case of sarcoidosis within
 a non-functioning pituitary adenoma, a case of intrasellar schwannoma coexisting with growth hormone (GH) secreting adenoma,
 two Rathke’s cleft cysts combined with pituitary adenomas, three gangliocytomas associated with GH-secreting adenomas, and
 a case of a double pituitary adenoma. The pertinent literature is discussed with emphasis on pathogenetic theories of dual
 sellar lesions. Although there is no direct evidence to confirm the pathogenetic relationship of collision sellar lesions,
 the number of cases presented in literature makes the theory of an incidental ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2516032</comments>
            <pubDate>Wed, 24 Jun 2009 06:11:23 +0100</pubDate>
            <guid isPermaLink="false">2516032</guid>        </item>
        <item>
            <title>Immunohistochemistry of COUP-TFI: an adjuvant diagnostic tool for the identification of corticotroph microadenomas</title>
            <link>http://www.medworm.com/index.php?rid=2477977&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy7j731662257328h%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cushing’s disease is caused by an ACTH-producing pituitary tumor, and accounts for 10–15% of pituitary tumors. The majority
 of corticotroph tumors are microadenomas (&amp;lt;10&amp;nbsp;mm), and accurate histologic identification of these tumors can be challenging
 because of their small size and the presence of nests of normal corticotroph cells in the anterior pituitary. Retinoic acid
 has been shown to inhibit ACTH production and induce apoptosis in corticotroph tumor cells. The expression of the orphan nuclear
 receptor COUP-TFI antagonizes retinoic acid signaling and has been shown to be expressed in normal corticotroph cells, but
 absent in corticotroph tumor cell lines. We analyzed 34 corticotroph tumor specimens by immunohistochemistry using a goat
 polyclonal IgG ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2477977</comments>
            <pubDate>Sat, 13 Jun 2009 07:56:30 +0100</pubDate>
            <guid isPermaLink="false">2477977</guid>        </item>
        <item>
            <title>Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=2477978&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu186366mp2458826%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this study was to assess the effects of replacement with recombinant human growth hormone (rhGH) in patients with
 GH deficiency (GHD) after treatment of acromegaly. Intervention study. Sixteen patients (8 men, age 56&amp;nbsp;years), treated for
 acromegaly by surgery and radiotherapy, with an insufficient GH response to insulin-induced hypoglycaemia, were treated with
 1&amp;nbsp;year of rhGH replacement. Study parameters were assessed at baseline and after 1&amp;nbsp;year of rhGH replacement. Study parameters
 were cardiac function, body composition, bone mineral density (BMD), fasting lipids, glucose, bone turnover markers, and Quality
 of Life (QoL). During rhGH replacement IGF-I concentrations increased from −0.4&amp;nbsp;±&amp;nbsp;0.7 to 1.0&amp;nbsp;±&amp;nbsp;1.5 SD (P&amp;nbs...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2477978</comments>
            <pubDate>Fri, 12 Jun 2009 11:33:27 +0100</pubDate>
            <guid isPermaLink="false">2477978</guid>        </item>
        <item>
            <title>Pituitary and systemic autoimmunity in a case of intrasellar germinoma</title>
            <link>http://www.medworm.com/index.php?rid=2437766&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F96227l2k1249g530%2F</link>
            <description>We report the case of an 11-year-old girl who presented with diabetes insipidus and growth retardation,
 and was found to have an intra- and supra-sellar mass. Initial examination of the pituitary biopsy showed diffuse lymphocytic
 infiltration of the adenohypophysis and absent placental alkaline phosphatase expression, leading to a diagnosis of hypophysitis
 and glucocorticoid treatment. Because of the lack of clinical and radiological response, the pituitary specimen was re-examined,
 revealing this time the presence of scattered c-kit and Oct4 positive germinoma cells. The revised diagnosis prompted the
 initiation of radiotherapy, which induced disappearance of the pituitary mass. Immunological studies showed that the patient’s
 serum recognized antigens expressed by the patient’s ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2437766</comments>
            <pubDate>Mon, 25 May 2009 05:49:10 +0100</pubDate>
            <guid isPermaLink="false">2437766</guid>        </item>
        <item>
            <title>Prevalence and clinical demographics of cerebral salt wasting in patients with aneurysmal subarachnoid hemorrhage</title>
            <link>http://www.medworm.com/index.php?rid=2432802&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw21410x1861052pv%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hyponatremia is a frequent complication following subarachnoid hemorrhage (SAH), and is commonly attributed either to the
 syndrome of inappropriate antidiuretic hormone secretion (SIADH) or cerebral salt wasting syndrome (CSW). The object of this
 study is to elucidate the clinical demographics and sequelae of hyponatremia due to CSW in subjects with aneurysmal SAH. Retrospective
 chart review of patients &amp;gt;18&amp;nbsp;years with aneurysmal SAH admitted between January 2004 and July 2007 was performed. Subjects
 with moderate to severe hyponatremia (serum sodium &amp;lt;130&amp;nbsp;mmol&amp;nbsp;l−1) were divided into groups consistent with CSW and SIADH based on urine output, fluid balance, natriuresis, and response to
 saline infusion. Clinical demographics were compared. Of 31...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2432802</comments>
            <pubDate>Fri, 22 May 2009 05:49:22 +0100</pubDate>
            <guid isPermaLink="false">2432802</guid>        </item>
        <item>
            <title>Pituicytoma and isolated ACTH deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2383944&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F45u8557u14k50503%2F</link>
            <description>Content Type Journal ArticleCategory LetterDOI 10.1007/s11102-009-0185-zAuthors
		John J. Orrego, Kaiser Permanente Department of Endocrinology and Metabolism 280 Exempla Circle Lafayette CO 80026 USA
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2383944</comments>
            <pubDate>Fri, 01 May 2009 06:51:22 +0100</pubDate>
            <guid isPermaLink="false">2383944</guid>        </item>
        <item>
            <title>Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique</title>
            <link>http://www.medworm.com/index.php?rid=2383945&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fuh50581661m50t20%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The background and aim of the study is to evaluate insulin sensitivity in hyperprolactinemic subjects via euglycemic hyperinsulinemic
 clamp technique. Sixteen hyperprolactinemic subjects and 12 healthy subjects were included in the study. HOMA-B and HOMA-IR
 values of groups were calculated. Euglycemic hyperinsulinemic clamp technique was performed in both groups, and the M value of the groups was defined. Mann–Whitney U and chi-square tests were used in statistical analysis. Basal insulin level of hyperprolactinemic patients were higher than
 the control group (6.85&amp;nbsp;±&amp;nbsp;4.68; 3.66&amp;nbsp;±&amp;nbsp;0.88&amp;nbsp;μU/ml respectively; P&amp;nbsp;&amp;lt;&amp;nbsp;0.05). Mean HOMA-IR and HOMA-B values of patients were higher than control group (1.49&amp;nbsp;±&amp;nbsp;1.30; 0.78&amp;nbsp;±...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2383945</comments>
            <pubDate>Fri, 01 May 2009 06:51:21 +0100</pubDate>
            <guid isPermaLink="false">2383945</guid>        </item>
        <item>
            <title>Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty</title>
            <link>http://www.medworm.com/index.php?rid=3098077&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F44r7pr56847u4710%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To determine utility of luteinizing hormone (LH) estimation, post intramuscular (IM) depot leuprolide in comparison with subcutaneous
 leuprolide stimulation test. Test for monitoring therapy in patients with gonadotropin dependent precocious puberty (GDPP).
 In seven patients of GDPP, who were treated with 11.25&amp;nbsp;mg depot leuprolide, the LH peak after subcutaneous (sc) test was compared
 with LH at hourly interval for 4&amp;nbsp;h after IM depot leuprolide for 13 tests and 3rd hour value for next ten tests. These two
 values were compared both before and after therapy. Before therapy, the mean&amp;nbsp;±&amp;nbsp;SD LH peak after subcutaneous leuprolide stimulation
 test was 20.6&amp;nbsp;±&amp;nbsp;7.85&amp;nbsp;IU/l (range 9.64–30.4&amp;nbsp;IU/l), and it was 27.3&amp;nbsp;±&amp;nbsp;12.21&amp;nbs...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3098077</comments>
            <pubDate>Sun, 26 Apr 2009 05:48:43 +0100</pubDate>
            <guid isPermaLink="false">3098077</guid>        </item>
        <item>
            <title>Utility of single luteinizing hormone determination 3 h after depot leuprolide in monitoring therapy of gonadotropin-dependent precocious puberty</title>
            <link>http://www.medworm.com/index.php?rid=2371101&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F44r7pr56847u4710%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To determine utility of luteinizing hormone (LH) estimation, post intramuscular (IM) depot leuprolide in comparison with subcutaneous
 leuprolide stimulation test. Test for monitoring therapy in patients with gonadotropin dependent precocious puberty (GDPP).
 In seven patients of GDPP, who were treated with 11.25&amp;nbsp;mg depot leuprolide, the LH peak after subcutaneous (sc) test was compared
 with LH at hourly interval for 4&amp;nbsp;h after IM depot leuprolide for 13 tests and 3rd hour value for next ten tests. These two
 values were compared both before and after therapy. Before therapy, the mean&amp;nbsp;±&amp;nbsp;SD LH peak after subcutaneous leuprolide stimulation
 test was 20.6&amp;nbsp;±&amp;nbsp;7.85&amp;nbsp;IU/l (range 9.64–30.4&amp;nbsp;IU/l), and it was 27.3&amp;nbsp;±&amp;nbsp;12.21&amp;nbs...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2371101</comments>
            <pubDate>Sun, 26 Apr 2009 05:48:43 +0100</pubDate>
            <guid isPermaLink="false">2371101</guid>        </item>
        <item>
            <title>Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis</title>
            <link>http://www.medworm.com/index.php?rid=2371102&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3811x40377q32675%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Thyrotoxicosis might alter the hypothalamic-pituitary-adrenal (HPA) axis. We evaluated the effects of ghrelin and GHRP-6 on
 the HPA axis in 20 hyperthyroid patients and in 9 controls. Mean basal cortisol (μg/dl) and ACTH (pg/ml) levels were higher
 in hyperthyroidism (cortisol: 10.7&amp;nbsp;±&amp;nbsp;0.7; ACTH: 21.5&amp;nbsp;±&amp;nbsp;2.9) compared to controls (cortisol: 8.1&amp;nbsp;±&amp;nbsp;0.7; ACTH: 13.5&amp;nbsp;±&amp;nbsp;1.8).
 In thyrotoxicosis &amp;#8710; AUC cortisol values (μg/dl.90&amp;nbsp;min) after ghrelin (484&amp;nbsp;±&amp;nbsp;80) and GHRP-6 (115&amp;nbsp;±&amp;nbsp;63) were similar to controls
 (ghrelin: 524&amp;nbsp;±&amp;nbsp;107; GHRP-6: 192&amp;nbsp;±&amp;nbsp;73). A significant increase in &amp;#8710; AUC ACTH (pg/ml.90&amp;nbsp;min) after ghrelin was observed in
 thyrotoxicosis (4,189&amp;nbsp;±&amp;nbsp;1,202) co...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2371102</comments>
            <pubDate>Sun, 26 Apr 2009 05:48:42 +0100</pubDate>
            <guid isPermaLink="false">2371102</guid>        </item>
        <item>
            <title>Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency</title>
            <link>http://www.medworm.com/index.php?rid=2367865&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F24u5013h31247n75%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The purpose of this study was to evaluate the effects of 5&amp;nbsp;years of GH substitution on cardiac structure and function, physical
 work capacity and blood pressure levels in adults with GH deficiency (GHD). Fourteen patients were clinically assessed every
 3&amp;nbsp;months for 5&amp;nbsp;years. Transthoracic echocardiography and exercise test were performed at baseline, 24, 48 and 60&amp;nbsp;months. Blood
 pressure (BP) was measured by means of ambulatory monitoring of blood pressure at baseline, 6, 12, 24 and 60&amp;nbsp;months. Left
 ventricular mass and its index increased progressively during the 5&amp;nbsp;years of GH substitution (P&amp;nbsp;=&amp;nbsp;0.008 and 0.007, respectively). There were no significant changes in all others cardiac parameters evaluated. It was observed
 a signifi...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2367865</comments>
            <pubDate>Fri, 24 Apr 2009 07:15:46 +0100</pubDate>
            <guid isPermaLink="false">2367865</guid>        </item>
        <item>
            <title>The diagnostic value of fused positron emission tomography/computed tomography in the localization of adrenocorticotropin-secreting pituitary adenoma in Cushing’s disease</title>
            <link>http://www.medworm.com/index.php?rid=2366109&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg41r5x1324121071%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Despite the high resolution of magnetic resonance imaging (MRI) of the pituitary gland, up to 40% of cases of Cushing’s disease
 (CD) have normal MRI. Fused images of positron emission tomography and computed tomography (PET-CT) may have a potential diagnostic
 role in CD in general and in such cases in particular. Objective of this study is to explore the diagnostic potential of PET-CT
 for localization of adrenocorticotropin-secreting pituitary adenomas in CD. PET-CT was performed in 12 cases with de novo
 (7 cases) or persistent CD (5 cases) that were proven to have CD on biochemical, radiological and/or histopathological findings.
 These cases had a definite CD confirmed on histopathological and immunostaining examination of the subsequent transphenoidal
 surgical...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2366109</comments>
            <pubDate>Thu, 23 Apr 2009 08:16:38 +0100</pubDate>
            <guid isPermaLink="false">2366109</guid>        </item>
        <item>
            <title>Brain and optic chiasmal herniations into sella after cabergoline therapy of giant prolactinoma</title>
            <link>http://www.medworm.com/index.php?rid=2358198&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1x87j732569262t6%2F</link>
            <description>We report a young
 man who developed secondary visual loss and seizures after 6&amp;nbsp;months of medical treatment with cabergoline for giant prolactinoma.
 Magnetic resonance imaging of hypothalamic pituitary region revealed optic chiasmal and frontal lobe herniation into sella.
 There was marginal improvement in his vision after cabergoline dose reduction. The present case report highlights frontal
 lobe herniation in conjunction with optic chiasmal herniation as a very rare complication of medical therapy of giant prolactinoma.
 Different treatment options of this condition are being discussed.
 
	Content Type Journal ArticleCategory CASE REPORTDOI 10.1007/s11102-009-0179-xAuthors
		Dinesh Kumar Dhanwal, Maulana Azad Medical College Department of Medicine and Division of Endocrinology 115...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2358198</comments>
            <pubDate>Tue, 21 Apr 2009 11:24:54 +0100</pubDate>
            <guid isPermaLink="false">2358198</guid>        </item>
        <item>
            <title>Effects of physical training on serum and pituitary growth hormone contents in diabetic rats</title>
            <link>http://www.medworm.com/index.php?rid=2343425&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv672502164q05868%2F</link>
            <description>In conclusion, physical training recovered serum IGF-I showing no alteration
 of serum or pituitary GH levels.
 
	Content Type Journal ArticleDOI 10.1007/s11102-009-0178-yAuthors
		José Alexandre Curiacos de Almeida Leme, São Paulo State University (UNESP) Department of Physical Education Avenida 24A no. 1515 Caixa Postal 199 Bela Vista, Rio Claro São Paulo CEP 13506-900 BrazilMichel Barbosa de Araújo, São Paulo State University (UNESP) Department of Physical Education Avenida 24A no. 1515 Caixa Postal 199 Bela Vista, Rio Claro São Paulo CEP 13506-900 BrazilLeandro Pereira de Moura, São Paulo State University (UNESP) Department of Physical Education Avenida 24A no. 1515 Caixa Postal 199 Bela Vista, Rio Claro São Paulo CEP 13506-900 BrazilRicardo José Gomes, São Paulo State Univer...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2343425</comments>
            <pubDate>Thu, 16 Apr 2009 05:49:48 +0100</pubDate>
            <guid isPermaLink="false">2343425</guid>        </item>
        <item>
            <title>Multiple head and neck tumors following treatment for craniopharyngioma</title>
            <link>http://www.medworm.com/index.php?rid=2333379&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg00j7210081v2270%2F</link>
            <description>We present a unique case of a young female who underwent
 resection and radiation treatment for a craniopharyngioma in 1988. With the exception of bitemporal visual loss and panhypopituitarism
 requiring hormone replacement therapy, the patient had a relatively uneventful course until 2005. At that time, she developed
 hearing loss and incapacitating vertigo, which was ultimately attributed to a temporal bone Langerhans histiocytosis. A year
 and a half later, she was noted to have a thyroid nodule, the pathology of which revealed papillary carcinoma. Seven months
 after that, she developed new auditory and vestibular symptoms attributable to an acoustic neuroma. This case is remarkable
 because neither Langerhans histiocytosis following radiation of a craniopharyngioma nor this distinctiv...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2333379</comments>
            <pubDate>Thu, 09 Apr 2009 07:09:27 +0100</pubDate>
            <guid isPermaLink="false">2333379</guid>        </item>
        <item>
            <title>Hematologic neoplasias and acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=2308385&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr44j72048p958427%2F</link>
            <description>We report a 59-year-old acromegalic woman, who presented with generalized bone pain, weakness, fatigue and foamy urine, who
 was found to have multiple myeloma (MM); and a 60-year-old acromegalic woman with dizziness, vomiting and abdominal pain,
 high blood pressure and splenomegaly that was posteriorly diagnosed as having Waldenstrom’s macroglobulinemia (WM). Acromegaly
 is an uncommon disease and epidemiological studies have provided increasingly debated evidence that elevated IGF-I levels
 might enhance the neoplastic risk, and that cancers constitute the third leading cause of mortality in acromegaly. It is known
 that GH and IGF-I can activate B cell lymphocytes, and that IGF-I receptor is universally expressed in MM cells. Although
 the complication of acromegaly with WM or MM in ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2308385</comments>
            <pubDate>Wed, 01 Apr 2009 06:08:03 +0100</pubDate>
            <guid isPermaLink="false">2308385</guid>        </item>
        <item>
            <title>Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment</title>
            <link>http://www.medworm.com/index.php?rid=2308386&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4248008720515t8k%2F</link>
            <description>This study analyzes SSTR’s expression
 in somatotrophinomas, comparing to SA response, hormonal levels, and tumor volume. We analyzed 39 somatotrophinomas; 49% were
 treated with SA. The most expressed SSTR was SSTR5, SSTR3, SSTR2, SSTR1, and SSTR4, respectively. SSTR1 and SSTR2 had higher
 expression in patients that had normalized GH and IGF-I. SSTR3 was more expressed in patients with tumor reduction. There
 was a positive correlation between the percentage of tumor reduction and SSTR1, SSTR2 and SSTR3 expression. Also, a positive
 correlation between SSTR2 mRNA expression and the immunohistochemical reactivity of SSTR2 was found. Our study confirmed the
 association between the SA response to GH and IGF-I and the SSTR2. Additionally, this finding was also demonstrated in relation
 to...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2308386</comments>
            <pubDate>Sat, 28 Mar 2009 09:08:51 +0100</pubDate>
            <guid isPermaLink="false">2308386</guid>        </item>
        <item>
            <title>Differential diagnosis of ACTH-dependent hypercortisolism: imaging versus laboratory</title>
            <link>http://www.medworm.com/index.php?rid=2277113&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F734w44q11642620q%2F</link>
            <description>In conclusion, imaging may prove unsatisfactory or even misleading for the etiologial diagnosis
 of ACTH-dependent Cushing’s syndrome and should therefore be interpreted only in context with results of hormonal dynamic
 testing.
 
	Content Type Journal ArticleDOI 10.1007/s11102-009-0174-2Authors
		Massimiliano Andrioli, University of Milan Chair of Endocrinology, Ospedale San Luca IRCCS, Istituto Auxologico Italiano Via Spagnoletto 3 20149 Milan ItalyFrancesca Pecori Giraldi, University of Milan Chair of Endocrinology, Ospedale San Luca IRCCS, Istituto Auxologico Italiano Via Spagnoletto 3 20149 Milan ItalyMartina De Martin, University of Milan Chair of Endocrinology, Ospedale San Luca IRCCS, Istituto Auxologico Italiano Via Spagnoletto 3 20149 Milan ItalyAgnese Cattaneo, University of M...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2277113</comments>
            <pubDate>Wed, 18 Mar 2009 06:52:00 +0100</pubDate>
            <guid isPermaLink="false">2277113</guid>        </item>
        <item>
            <title>Efficacy of long-term lanreotide treatment in patients with acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=2248730&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F35p4g474jm12r111%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We investigated the effectiveness of lanreotide for the treatment of active acromegaly in a retrospectively multicenter case
 series including 53 patients (24 male, 29 female; mean age at diagnosis, 49.5&amp;nbsp;±&amp;nbsp;13.9&amp;nbsp;years) with acromegaly treated with lanreotide
 in nine different centers. Mean tumor diameter was 20&amp;nbsp;±&amp;nbsp;13&amp;nbsp;mm; mean basal levels of growth hormone (GH) and insulin-like growth
 factor I (IGF-I) were 21.3&amp;nbsp;±&amp;nbsp;26.3 and 579&amp;nbsp;±&amp;nbsp;177&amp;nbsp;μg/l, respectively. The primary mode of treatment was surgery in 70% of patients.
 Twenty-nine patients received only lanreotide (Prolonged Release, Autogel), whereas 24 subjects were also treated with octreotide
 at another treatment stage. Primary therapy with lanreotide was admini...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2248730</comments>
            <pubDate>Fri, 06 Mar 2009 10:51:30 +0100</pubDate>
            <guid isPermaLink="false">2248730</guid>        </item>
        <item>
            <title>Self-limited acute hepatotoxicity caused by pegvisomant</title>
            <link>http://www.medworm.com/index.php?rid=2248731&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft1u53731814q6338%2F</link>
            <description>We present a case of acute severe hepatitis in a patient with acromegaly receiving combination therapy with somatostatin analogs
 and pegvisomant. Hepatitis resolved completely 18&amp;nbsp;weeks after diagnosis of hypertransaminasemia without discontinuation of
 therapy and with a close clinical and biochemical follow-up. In this case, despite the severity of the hepatitis, therapy
 could be continued as hypertransaminasemia was gradually decreasing after the maximum peak. We also review the literature
 on toxic hepatitis associated to pegvisomant therapy analyzing the etiology, clinical predisposing factors and natural evolution.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-009-0173-3Authors
		A. Soto Moreno, Virgen del Rocio University Hospital Department of Endocrin...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2248731</comments>
            <pubDate>Fri, 06 Mar 2009 10:51:27 +0100</pubDate>
            <guid isPermaLink="false">2248731</guid>        </item>
        <item>
            <title>Simultaneous above and below approach to giant pituitary adenomas: surgical strategies and long-term follow-up</title>
            <link>http://www.medworm.com/index.php?rid=2221565&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv17x714h2415724j%2F</link>
            <description>Conclusions The addition of a transcranial component to the transsphenoidal approach offers additional visualization of critical neurovascular
 structures during giant pituitary adenoma resection. Complications rates are similar to other series in which complex pituitary
 adenomas are resected by other means. The above and below approach is both safe and effective and the immediate and long-term
 advantages of a single-stage approach justify its utility in this select group of patients.
 
	Content Type Journal ArticleDOI 10.1007/s11102-009-0171-5Authors
		Anthony L. D’Ambrosio, Columbia University Medical Center Department of Neurological Surgery, New York Presbyterian Hospital New York NY USAOmar N. Syed, Columbia University Medical Center Department of Neurological Surgery, New York Pr...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2221565</comments>
            <pubDate>Thu, 26 Feb 2009 11:48:44 +0100</pubDate>
            <guid isPermaLink="false">2221565</guid>        </item>
        <item>
            <title>Recurrent spindle cell oncocytoma of the pituitary, a case report and review of literature</title>
            <link>http://www.medworm.com/index.php?rid=2221566&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fnv34313q63481m2u%2F</link>
            <description>We report a case of SCO who presented with symptoms of
 visual blurring, weight loss, intermittent vomiting and excessive tiredness of several months duration. Investigations revealed
 a bitemporal visual field defect, a panhypopituitary hormonal profile and a large pituitary tumour with suprasellar extension.
 He underwent a successful trans-sphenoidal resection of the pituitary tumour but it subsequently recurred twice at 9&amp;nbsp;months
 interval which required further two debulking procedures. A diagnosis of SCO was made based on its unique histologic and staining
 properties. To date there are only ten reported cases of SCO in total with only two of these cases being recurrent. Our case
 displayed the most aggressive clinical course despite having a low Ki-67 index contrary to the previ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2221566</comments>
            <pubDate>Wed, 25 Feb 2009 10:13:34 +0100</pubDate>
            <guid isPermaLink="false">2221566</guid>        </item>
        <item>
            <title>Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review</title>
            <link>http://www.medworm.com/index.php?rid=2163095&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F954462kv0746ju12%2F</link>
            <description>We describe a case of a 57-year-old woman who presented with a large macroprolactinoma with suprasellar
 extension. She was initially treated with bromocriptine therapy with a resolution of symptoms, marked reduction in prolactin
 concentration and complete tumour shrinkage; a response which was subsequently maintained on cabergoline. After 8&amp;nbsp;years of
 dopamine agonist therapy, her prolactin concentration began to rise and there was symptomatic recurrence of her tumour despite
 escalating doses of cabergoline up to 6&amp;nbsp;mg weekly. Non-compliance was outruled by observed inpatient drug administration.
 The patient underwent surgical debulking followed by radiotherapy with good response. This case adds to the previous two cases
 of secondary resistance to cabergoline therapy in prolac...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2163095</comments>
            <pubDate>Wed, 04 Feb 2009 13:45:57 +0100</pubDate>
            <guid isPermaLink="false">2163095</guid>        </item>
        <item>
            <title>Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review</title>
            <link>http://www.medworm.com/index.php?rid=2159926&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl31317876w72m32t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Long-acting somatostatin analogs (SSA) are widely used for the treatment of acromegaly achieving biochemical control of the
 disease in 50–75% of the patients. One of the goals of the treatment of acromegaly is the control of tumor growth, especially
 in patients in whom SSAs are used as first-line therapy. Over the recent years, there has been growing evidence that SSAs
 are able to induce tumor shrinkage in patients with acromegaly. However, most of the data are from patients under treatment
 with octreotide, either subcutaneously or intramuscularly with long-acting formulation, whereas the data on lanreotide SR
 or Autogel are very few. Indeed, octreotide and lanreotide, i.e. the two commercially available SSAs, show slight differences
 in pharmacokinetics and patt...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2159926</comments>
            <pubDate>Tue, 03 Feb 2009 07:08:43 +0100</pubDate>
            <guid isPermaLink="false">2159926</guid>        </item>
        <item>
            <title>The implications of microsurgical anatomy for surgical approaches to the sellar region</title>
            <link>http://www.medworm.com/index.php?rid=2147145&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk1876x758550201u%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The knowledge of the normal anatomy and variations regarding the management of tumors of the sellar region is paramount to
 perform safe surgical procedures. The sellar region is located in the center of the middle cranial fossa; it contains complex
 anatomical structures, and is the site of various pathological processes: tumor, vascular, developmental, and neuroendocrine.
 We review the microsurgical anatomy (microscopic and endoscopic) of this region and discuss the surgical nuances regarding
 this topic, based on anatomical concepts.
 
	Content Type Journal ArticleDOI 10.1007/s11102-009-0167-1Authors
		Gustavo Rassier Isolan, Pontifical Catholic University of Paraná Department of Neurosurgery Curitiba BrazilPaulo Henrique Pires de Aguiar, State University of Sao Pa...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2147145</comments>
            <pubDate>Thu, 29 Jan 2009 08:24:04 +0100</pubDate>
            <guid isPermaLink="false">2147145</guid>        </item>
        <item>
            <title>Adjuvant Gamma Knife radiosurgery in non-functioning pituitary adenomas; low risk of long-term complications in selected patients</title>
            <link>http://www.medworm.com/index.php?rid=2120607&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd7362w1h6257287n%2F</link>
            <description>This report suggests
 that in well-selected patients the long-term risk of complications is low and with careful surveillance GH insufficiency can
 be replaced. Lifelong follow-up is mandatory.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0163-xAuthors
		Charlotte Höybye, Karolinska University Hospital Department of Endocrinology, Metabolism and Diabetology 171 76 Solna, Stockholm SwedenTiit Rähn, Karolinska University Hospital Department of Neurosurgery 171 76 Solna, Stockholm Sweden
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2120607</comments>
            <pubDate>Mon, 19 Jan 2009 08:02:29 +0100</pubDate>
            <guid isPermaLink="false">2120607</guid>        </item>
        <item>
            <title>Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma</title>
            <link>http://www.medworm.com/index.php?rid=2115172&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F57p67722v1226210%2F</link>
            <description>We report the
 history of an adolescent male who was diagnosed with a large invasive macroprolactinoma in 2002. He had severe bitemporal
 hemianopsia and hypopituitarism; prolactin levels at diagnosis were higher than 8,000&amp;nbsp;ng/ml. Medical therapy with cabergoline
 was initiated and resulted in decreased prolactin levels but not complete normalisation (maximal tolerated dose 3&amp;nbsp;mg/day).
 However, due to the worsening of the visual defect, the patient was operated in July 2004 through the trans-nasal approach
 and 2&amp;nbsp;years later through both the transcranial and the transphenoidal approaches. After the second surgery, a significant
 reduction of tumour mass was obtained. Immunohistochemistry for somatostatin receptors (sstr) subtypes showed a positive staining
 with the anti-sst...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2115172</comments>
            <pubDate>Sat, 17 Jan 2009 09:00:16 +0100</pubDate>
            <guid isPermaLink="false">2115172</guid>        </item>
        <item>
            <title>Craniopharyngioma: historical notes</title>
            <link>http://www.medworm.com/index.php?rid=2094494&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr914365522350314%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;For centuries tumors have been described which today with some confidence can be diagnosed as craniopharyngiomas. It was not
 until 1904 Erdheim described what he called ‘hypophysial duct tumors’, and which Cushing later gave the name craniopharyngioma.
 The first operation for this neoplasm took place in 1909. It soon became evident that the outcome of surgery was rather dismal
 with high mortality and morbidity rates—even after corticosteroid therapy became available around 1950. Radiotherapy was introduced
 and later refined as radiosurgery. This paper presents a short survey of the accumulation of knowledge of craniopharyngiomas.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0165-8Authors
		J. Lindholm, Aarhus University Hospital Department of Endocrin...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2094494</comments>
            <pubDate>Thu, 08 Jan 2009 08:58:13 +0100</pubDate>
            <guid isPermaLink="false">2094494</guid>        </item>
        <item>
            <title>Primary CNS lymphoma with bilateral symmetric hypothalamic lesions presenting with panhypopituitarism and diabetes insipidus</title>
            <link>http://www.medworm.com/index.php?rid=2086538&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3g89r47jw6m58324%2F</link>
            <description>We present an unusual case of primary central nervous system (CNS) lymphoma presenting with bilateral symmetric hypothalamic
 lesions causing diabetes insipidus and hypopituitarism. A 50-year-old male presented initially with mental status changes,
 polyuria and polydipsia. The patient was determined to have diabetes insipidus (DI) and significant anterior pituitary deficiencies
 resulting in symptomatic pleural and pericardial effusions. Brain MRI with contrast demonstrated bilateral enhancement of
 his hypothalamus extending to the optic tract. The extensive diagnostic workup that ensued on his initial presentation was
 non-diagnostic as he had no obvious site of involvement that was easily accessible to biopsy. With close follow-up, the patient
 had rapid radiographic progression of his...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2086538</comments>
            <pubDate>Sat, 03 Jan 2009 06:47:52 +0100</pubDate>
            <guid isPermaLink="false">2086538</guid>        </item>
        <item>
            <title>Sellar and suprasellar mixed germ cell tumor mimicking a pituitary adenoma</title>
            <link>http://www.medworm.com/index.php?rid=2072937&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv26g627016h5x622%2F</link>
            <description>In conclusion, although pituitary adenomas
 respond for the vast majority of sellar tumors, concomitant symptoms such as central diabetes insipidus and rapid tumor growth should raise the suspicion of a diverse diagnosis. The present report intend not only to show a rare
 case of sellar and suprasellar mixed GCT but also to remind clinicians that if laboratory findings do not fit into patient’s
 diagnosis (such as high testosterone levels in our patient), then the diagnosis should be reviewed.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0161-zAuthors
		Luiz Eduardo Armondi Wildemberg, Universidade Federal do Rio de Janeiro (UFRJ) Endocrinology Unit, Hospital Universitário Clementino Fraga Filho Rio de Janeiro BrazilLeonardo Vieira Neto, Universidade Federal...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2072937</comments>
            <pubDate>Wed, 31 Dec 2008 09:34:15 +0100</pubDate>
            <guid isPermaLink="false">2072937</guid>        </item>
        <item>
            <title>Isolated acquired ACTH deficiency and primary hypothyroidism: a short series and review</title>
            <link>http://www.medworm.com/index.php?rid=2072938&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F28612105k2275152%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Idiopathic isolated ACTH deficiency, congenital or acquired, is rare. It may be found in association with primary hypothyroidism.
 Here we describe four cases of acquired idiopathic isolated ACTH deficiency illustrating its importance and variable presentation.
 All cases had a structurally normal pituitary gland and persistently normal residual pituitary function. Three cases had co-existing
 primary hypothyroidism. We discuss the protean presentation of this rare but important condition, its treatment, associations,
 and possible aetiologies.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0164-9Authors
		M. J. Hannon, Cork University Hospital Department of Endocrinology and Metabolism Wilton, Cork IrelandD. J. O’Halloran, Cork University H...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2072938</comments>
            <pubDate>Sun, 28 Dec 2008 07:05:48 +0100</pubDate>
            <guid isPermaLink="false">2072938</guid>        </item>
        <item>
            <title>Unusual clinical presentations of giant prolactinomas</title>
            <link>http://www.medworm.com/index.php?rid=2064861&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu3n8578071257822%2F</link>
            <description>We describe three men with
 unusual presenting features of prolactin-secreting giant pituitary adenomas: prolonged and increasingly disturbing intolerance
 to light and noise; strange behavior and mood disturbances; and rhinorrhea followed by a finding of cerebrospinal fluid leakage.
 Treatment with dopamine agonist alleviated all symptoms, with concomitant suppression of plasma prolactin levels and a significant
 reduction in tumor mass. These cases emphasize the importance of considering unusual symptoms in the differential diagnosis
 of giant prolactinomas and the effectiveness of medical treatment.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0160-0Authors
		Simona Grozinsky-Glasberg, Institute of Endocrinology &amp; Metabolism, Rabin Medical Center, Beilinson ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2064861</comments>
            <pubDate>Tue, 23 Dec 2008 08:10:10 +0100</pubDate>
            <guid isPermaLink="false">2064861</guid>        </item>
        <item>
            <title>Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=2051789&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F63502554p1586643%2F</link>
            <description>Conclusion    the GHR genotype could be useful in predicting dose and individual response to pegvisomant in acromegaly.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0157-8Authors
		Antonio Bianchi, Catholic University Division of Endocrinology, School of Medicine Largo A. Gemelli, 8 00168 Rome ItalyGherardo Mazziotti, University of Brescia Department of Medical and Surgical Sciences Brescia ItalyLaura Tilaro, Catholic University Division of Endocrinology, School of Medicine Largo A. Gemelli, 8 00168 Rome ItalyVincenzo Cimino, Catholic University Division of Endocrinology, School of Medicine Largo A. Gemelli, 8 00168 Rome ItalyFlora Veltri, Catholic University Division of Endocrinology, School of Medicine Largo A. Gemelli, 8 00168 Rome ItalyEleonora Gaetani, Catholic Univer...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2051789</comments>
            <pubDate>Wed, 17 Dec 2008 08:33:06 +0100</pubDate>
            <guid isPermaLink="false">2051789</guid>        </item>
        <item>
            <title>The molecular biology of pituitary tumors: a personal perspective</title>
            <link>http://www.medworm.com/index.php?rid=2016472&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F22vr167604377385%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Oncogenes and tumor suppressor genes involved in most common cancers are not involved in the great majority of pituitary adenomas.
 Similarly, there is little evidence to suggest that the mutations involved in genetic syndromes associated with pituitary
 tumors (such as the gsp, MEN1, PKAR1A or AIP mutations) are common in sporadic tumors. A novel pituitary tumor transforming
 gene (PTTG, securin) has been identified which is over-expressed in most tumors—but it is unclear as to its causal role in
 oncogenesis. Cell signaling abnormalities have been identified in pituitary tumors but their genetic basis is unknown. However,
 both the Akt pathway and the MAPK pathway are over-expressed in many pituitary tumors, which results in the inhibition of
 cell cycle inhibitors....</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2016472</comments>
            <pubDate>Fri, 05 Dec 2008 09:29:59 +0100</pubDate>
            <guid isPermaLink="false">2016472</guid>        </item>
        <item>
            <title>Successful treatment of Cushing’s disease caused by ectopic intracavernous microadenoma</title>
            <link>http://www.medworm.com/index.php?rid=2013166&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F63257g61264w0103%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas are sometimes difficult to visualize, even with high-quality
 magnetic resonance imaging, due to their small size and variable location. Sampling the cavernous or inferior petrosal sinus
 is helpful for confirming the central origin of a tumor, but ectopic corticotroph adenomas in the paraseller region also typically
 exhibit a high central/peripheral plasma ACTH ratio. We experienced an extremely rare case of Cushing’s disease caused by
 an ACTH-secreting microadenoma located entirely inside the left cavernous sinus attached to the medial wall (ectopic pituitary
 adenoma) that was not visible by preoperative MRI. In this case, the microadenoma was completely removed and an endocrinologic
 cure was achiev...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2013166</comments>
            <pubDate>Wed, 03 Dec 2008 08:18:39 +0100</pubDate>
            <guid isPermaLink="false">2013166</guid>        </item>
        <item>
            <title>Pituitary-hormone secretion by thyrotropinomas</title>
            <link>http://www.medworm.com/index.php?rid=2013165&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn934g6u6u7255670%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hormone secretion by somatotropinomas, corticotropinomas and prolactinomas exhibits increased pulse frequency, basal and pulsatile
 secretion, accompanied by greater disorderliness. Increased concentrations of growth hormone (GH) or prolactin (PRL) are observed
 in about 30% of thyrotropinomas leading to acromegaly or disturbed sexual functions beyond thyrotropin (TSH)-induced hyperthyroidism.
 Regulation of non-TSH pituitary hormones in this context is not well understood. We there therefore evaluated TSH, GH and
 PRL secretion in 6 patients with up-to-date analytical and mathematical tools by 24-h blood sampling at 10-min intervals in
 a clinical research laboratory. The profiles were analyzed with a new deconvolution method, approximate entropy, cross-approximate
 en...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2013165</comments>
            <pubDate>Wed, 03 Dec 2008 08:18:39 +0100</pubDate>
            <guid isPermaLink="false">2013165</guid>        </item>
        <item>
            <title>Beta human chorionic gonadotropin (β-hCG) expression in pituitary adenomas: relationship to endocrine function and tumour recurrence</title>
            <link>http://www.medworm.com/index.php?rid=1959485&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Few41503992061550%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The β subunit of human chorionic gonadotropin (β-hCG) is a marker of malignancies. Recent studies have also reported its expression
 in pituitary adenomas, although its significance is unclear. In this retrospective study, the authors quantitatively investigated
 the immunohistochemical expression of β-hCG in 123 patients undergoing surgery for pituitary adenomas and explored its relationship
 to the rest of the endocrine function, tumour recurrence and Ki-67 nuclear labelling. Based on the endocrine profile and immunohistochemistry,
 the pituitary adenomas were grouped into non-functioning (NFPA; N&amp;nbsp;=&amp;nbsp;78) and functioning pituitary adenomas (N&amp;nbsp;=&amp;nbsp;45). The latter included, 20 growth hormone (GH), 12 prolactin (PRL), 8 adreno-corticotrophin hormone (A...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1959485</comments>
            <pubDate>Thu, 13 Nov 2008 16:06:32 +0100</pubDate>
            <guid isPermaLink="false">1959485</guid>        </item>
        <item>
            <title>Future treatment strategies of aggressive pituitary tumors</title>
            <link>http://www.medworm.com/index.php?rid=1959486&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F74078161585w0qtg%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;While surgery remains the first-line treatment of most aggressive pituitary adenomas, medical therapy is important as second-line
 or adjunctive therapy in a large proportion of patients. Dopamine agonists (DAs) are the best treatment for prolactinomas,
 but when DAs are not tolerated, new somatostatin receptor subtype 5 (SSTR5) inhibitors may offer an alternative in the future. Unfortunately, these are unlikely to be effective in DA-resistant prolactinomas.
 In acromegaly, the existing somatostatin analogs, octreotide and lanreotide, will remain the medical treatment of choice for
 the foreseeable future. There is an urgent need for medical therapies in Cushing’s disease, and the SSTR5 analogs could offer an effective treatment in a proportion of patients within the ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1959486</comments>
            <pubDate>Wed, 12 Nov 2008 22:25:06 +0100</pubDate>
            <guid isPermaLink="false">1959486</guid>        </item>
        <item>
            <title>Management of aggressive pituitary adenomas: current treatment strategies</title>
            <link>http://www.medworm.com/index.php?rid=1959487&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn44q2u782347587n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Aggressive pituitary adenomas are notoriously difficult to manage due to their size, invasiveness, speed of growth and high
 frequency of recurrence. Except for prolactinomas, surgery (usually transsphenoidal but sometimes transcranial) is the first-line
 option, but re-growth of aggressive tumors is almost inevitable and monitoring and repeat surgery is required to control symptoms.
 In prolactinomas, dopamine agonists are the first-line treatment and they normalize prolactin levels in most patients even
 with macroprolactinomas. Somatostatin analogues offer another pharmacotherapy for pituitary adenomas either for primary therapy,
 pre-operatively to reduce the tumor volume and make it more amenable to surgical removal, or post-surgery to control re-expansion.
 When s...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1959487</comments>
            <pubDate>Wed, 12 Nov 2008 22:25:05 +0100</pubDate>
            <guid isPermaLink="false">1959487</guid>        </item>
        <item>
            <title>Confirmation of local amino acid sequence homology between human prolactin and the amyloid-related proteins</title>
            <link>http://www.medworm.com/index.php?rid=1944900&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F2102q74481kj1l17%2F</link>
            <description>Content Type Journal ArticleCategory LetterDOI 10.1007/s11102-008-0152-0Authors
		S. Benvenga, Università di Messina Sezione di Endocrinologia del Dipartimento Clinico Sperimentale di Medicina e Farmacologia 98125 Messina ItalyS. Cannavò, Università di Messina Sezione di Endocrinologia del Dipartimento Clinico Sperimentale di Medicina e Farmacologia 98125 Messina ItalyF. Trimarchi, Università di Messina Sezione di Endocrinologia del Dipartimento Clinico Sperimentale di Medicina e Farmacologia 98125 Messina ItalyF. Guarneri, Università di Messina Istituto di Dermatologia 98125 Messina Italy
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1944900</comments>
            <pubDate>Thu, 06 Nov 2008 00:41:45 +0100</pubDate>
            <guid isPermaLink="false">1944900</guid>        </item>
        <item>
            <title>Primary pituitary abscess followed by empty sella syndrome in an adolescent girl</title>
            <link>http://www.medworm.com/index.php?rid=1911047&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv8403u01722171x2%2F</link>
            <description>We report the case of an adolescent girl presenting with headache, diabetes insipidus and central
 thyro-gonadic insufficiency with no history of infection, in whom the intra-operative diagnosis of primary pituitary abscess
 was made. Bacterial cultures indicated infection with Streptococcus spp. One year after neurosurgery and antibiotic therapy, recovery of diabetes insipidus and pituitary insufficiency was documented
 except for persistence of subnormal growth hormone secretion. Post-surgery, pituitary magnetic resonance imaging revealed
 an empty sella syndrome.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0150-2Authors
		Carmen Emanuela Pepene, University of Medicine and Pharmacy Department of Endocrinology Cluj-Napoca RomaniaIoana Ilie, University of Medi...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1911047</comments>
            <pubDate>Sat, 25 Oct 2008 08:54:54 +0100</pubDate>
            <guid isPermaLink="false">1911047</guid>        </item>
        <item>
            <title>Atypical pituitary adenoma with malignant features</title>
            <link>http://www.medworm.com/index.php?rid=1911048&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl71h6g3uh380rg55%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pituitary carcinoma is characterized by the presence of systemic or central nervous system metastases rather than malignant
 histological features, making it an anomaly amongst carcinomas. In contrast, aggressive or atypical pituitary adenomas often
 have a relatively bland histological appearance despite their malignant growth patterns. We now report a case of a 67-years-old
 male with a giant pituitary tumor with overt pathologic and phenotypic features of malignancy, but the absence of metastases,
 that evolved from a benign non-functioning gonadotroph macroadenoma treated 10 years earlier. This case represents the first
 report of a pituitary adenoma with overt malignant histology that does not meet criteria for classification as pituitary carcinoma,
 helping to com...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1911048</comments>
            <pubDate>Fri, 24 Oct 2008 06:55:04 +0100</pubDate>
            <guid isPermaLink="false">1911048</guid>        </item>
        <item>
            <title>Clinical profile and long term follow up of children and adolescents with prolactinomas</title>
            <link>http://www.medworm.com/index.php?rid=1905173&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb012t36484h1l0p3%2F</link>
            <description>In conclusion, the medical treatment with
 dopaminergic compounds is effective and safe in patients with prolactinoma with onset in childhood, allowing preservation
 of the anterior pituitary function.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0149-8Authors
		Shrikrishna V. Acharya, K E M Hospital Parel Mumbai 400012 Maharashtra IndiaRaju A. Gopal, K E M Hospital Parel Mumbai 400012 Maharashtra IndiaTushar R. Bandgar, K E M Hospital Parel Mumbai 400012 Maharashtra IndiaShashank R. Joshi, K E M Hospital Parel Mumbai 400012 Maharashtra IndiaPadma S. Menon, K E M Hospital Parel Mumbai 400012 Maharashtra IndiaNalini S. Shah, K E M Hospital Department of Endocrinology Parel Mumbai 400012 Maharashtra India
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pit...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1905173</comments>
            <pubDate>Thu, 23 Oct 2008 05:54:22 +0100</pubDate>
            <guid isPermaLink="false">1905173</guid>        </item>
        <item>
            <title>Pituitary radiotherapy</title>
            <link>http://www.medworm.com/index.php?rid=1905172&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu445u406vt8n8722%2F</link>
            <description>Content Type Journal ArticleCategory Guest EditorialDOI 10.1007/s11102-008-0148-9Authors
		Mark E. Molitch, Northwestern University Division of Endocrinology, Metabolism, and Molecular Medicine, Feinberg School of Medicine Chicago IL 60611 USAAshley B. Grossman, Barts and the London School of Medicine Centre for Endocrinology London UK
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1905172</comments>
            <pubDate>Thu, 23 Oct 2008 05:54:22 +0100</pubDate>
            <guid isPermaLink="false">1905172</guid>        </item>
        <item>
            <title>Acromegaly secondary to an incidentally discovered growth-hormone-releasing hormone secreting bronchial carcinoid tumour associated to a pituitary incidentaloma</title>
            <link>http://www.medworm.com/index.php?rid=1905171&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc0h51635777507x1%2F</link>
            <description>In this report we emphasize the opportunity of considering the uncommon causes of chronic GH-excess in the initial diagnostic
 process, such as GHRH hypersecretion, especially in the presence of ambiguous pituitary neuroimaging. This topic may have
 an important clinical significance in order to plan the most cost-effective diagnostic procedures and management and to avoid
 unnecessary pituitary neurosurgery.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0146-yAuthors
		E. Verrua, University of Milan Unit of Endocrinology, Department of Medical Sciences, Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena Via F. Sforza 35 20122 Milan ItalyC. L. Ronchi, University of Milan Unit of Endocrinology, Department of Medical Sciences, Fondazione IR...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1905171</comments>
            <pubDate>Thu, 23 Oct 2008 05:54:22 +0100</pubDate>
            <guid isPermaLink="false">1905171</guid>        </item>
        <item>
            <title>Pituitary gland and β-catenin signaling: from ontogeny to oncogenesis</title>
            <link>http://www.medworm.com/index.php?rid=1905174&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F30663n142172747v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Although pituitary tumors are mostly benign, they share certain molecular events with more malignant neoplasia, although their
 precise pathogenesis is far from established. The acquisition of new functional characteristics during their evolution suggests
 a multistep process that leads to tumor transformation. Mutations in classical tumor suppressor genes or oncogenes are infrequently
 associated with pituitary tumorigenesis. However, alterations in different signaling pathways, especially those involved in
 pituitary gland development, have emerged as significant features in pituitary adenomas. In particular, changes in inhibitory
 components of the β-catenin pathway and its relationship to the cadherin family of peptides may well play an important role
 in tumorigen...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1905174</comments>
            <pubDate>Thu, 23 Oct 2008 05:54:21 +0100</pubDate>
            <guid isPermaLink="false">1905174</guid>        </item>
        <item>
            <title>An unusual collision tumor comprising a prolactinoma and a plasmocytoma originating from the sellar region</title>
            <link>http://www.medworm.com/index.php?rid=1870270&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj706157553j52478%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A 58-year-old previously healthy man presented with diplopia of rapid onset over a few days. Examination demonstrated bilateral
 sixth and right fourth cranial nerve palsy. MR imaging showed a large sellar mass with significant destruction of the pituitary
 fossa. Laboratory tests revealed very high serum prolactin (2,483&amp;nbsp;ng/dl, reference range 3–13 ng/dl). Dopamine agonist therapy
 was initiated with significant decline in PRL levels; however, nausea, fatigue, and anorexia developed. Within a few weeks
 the patient developed renal failure and hypercalcemia. Urine protein electrophoresis revealed large free monoclonal kappa
 peaks while extensive plasmocytosis was evident in bone marrow aspirates. On bone scan numerous lytic lesions were present.
 A transsphenoid...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1870270</comments>
            <pubDate>Fri, 10 Oct 2008 08:17:43 +0100</pubDate>
            <guid isPermaLink="false">1870270</guid>        </item>
        <item>
            <title>Macroscopic brain architecture changes and white matter pathology in acromegaly: a clinicoradiological study</title>
            <link>http://www.medworm.com/index.php?rid=1855551&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw0357862u1886313%2F</link>
            <description>In conclusion, this MRI study provides first evidence that acromegalic patients exhibit disturbances of the macroscopic
 brain tissue architecture. Furthermore, acromegalic patients may have an increased risk of neurovascular pathology, likely
 due to secondary metabolic and vascular comorbidities.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0143-1Authors
		C. Sievers, Max Planck Institute of Psychiatry Department of Endocrinology Kraepelinstr. 2-10 80804 Munich GermanyP. G. Sämann, Max Planck Institute of Psychiatry Department of Magnetic Resonance Imaging Kraepelinstr. 2-10 80804 Munich GermanyT. Dose, Max Planck Institute of Psychiatry Department of Endocrinology and Department of Magnetic Resonance Imaging Kraepelinstr. 2-10 80804 Munich GermanyC. Dimopoulou, Max Planck Inst...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1855551</comments>
            <pubDate>Sat, 04 Oct 2008 09:29:46 +0100</pubDate>
            <guid isPermaLink="false">1855551</guid>        </item>
        <item>
            <title>Severe hypernatraemia associated with growth hormone replacement therapy in a patient with septo-optic dysplasia</title>
            <link>http://www.medworm.com/index.php?rid=1828831&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fbu352658522249tr%2F</link>
            <description>Conclusion Most GHD patients have intact posterior pituitary function. This case report highlights the powerful anti-natriuretic properties
 of GH. Endocrine physicians should be alert to this in patients with fixed DI and an abnormal thirst threshold.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0144-0Authors
		Shivani Misra, St Bartholomew’s Hospital Department of Endocrinology London EC1A 7BE UKLinda Brown Johnston, St Bartholomew’s Hospital Department of Endocrinology London EC1A 7BE UKWilliam Martyn Drake, St Bartholomew’s Hospital Department of Endocrinology London EC1A 7BE UK
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1828831</comments>
            <pubDate>Wed, 24 Sep 2008 08:30:52 +0100</pubDate>
            <guid isPermaLink="false">1828831</guid>        </item>
        <item>
            <title>Hypogonadotropic hypogonadism: a consequence of Chiari-I malformation</title>
            <link>http://www.medworm.com/index.php?rid=1811051&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu573168543404268%2F</link>
            <description>We describe a women with cystic fibrosis who presented
 with secondary amenorrhea as a consequence of Chiari-I malformation and resultant hydrocephalus. The biochemical picture was
 characterized by hypogonadotropic hypogonadism. Resolution of the amenorrhea was observed to occur following 3rd ventriculostomy.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0142-2Authors
		Sampath Satish Kumar, Leeds Teaching Hospitals NHS Trust Department of Endocrinology D Floor, Brotherton Wing, Leeds General Infirmary, Great George Street Leeds LS1 3EX UKPaul Chumas, Leeds Teaching Hospitals NHS Trust Department of Neurosurgery Leeds UKDaniel Peckham, Leeds Teaching Hospitals NHS Trust Department of Respiratory Medicine Leeds UKAshley Guthrie, Leeds Teaching Hospitals NHS Trus...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1811051</comments>
            <pubDate>Thu, 18 Sep 2008 06:44:49 +0100</pubDate>
            <guid isPermaLink="false">1811051</guid>        </item>
        <item>
            <title>Transient asystole during endoscopic transsphenoidal surgery: an example of trigeminocardiac reflex</title>
            <link>http://www.medworm.com/index.php?rid=1789991&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl282rn83p437ug41%2F</link>
            <description>Content Type Journal ArticleCategory ErratumDOI 10.1007/s11102-008-0141-3Authors
		Bernhard Schaller, University of Paris Departments of Neurosurgery Paris FranceNora Sandu, University of Paris Departments of Neurosurgery Paris FranceGiulia Ottaviani, University of Milano Centro ‘‘Lino Rossi’’ Research Center for the Study and Prevention of the Unexpected Perinatal Death and SIDS, Institute of Pediatrics and Neonatology Milan ItalyAndreas Filis, Erlangen GermanyChristoph Noethen, Erlangen GermanyMichael Buchfelder, Erlangen GermanyFor the Trigemino-Cardiac-Reflex-Examination-Group (T.C.R.E.G.), Paris France
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1789991</comments>
            <pubDate>Fri, 12 Sep 2008 07:54:03 +0100</pubDate>
            <guid isPermaLink="false">1789991</guid>        </item>
        <item>
            <title>The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia</title>
            <link>http://www.medworm.com/index.php?rid=1742026&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh78635t247g85457%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Leptin is a key mediator in the maintenance of neuroendocrine homeostasis. The aim of this study was to determine the changes
 in serum leptin, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), nitric oxide (NO) levels in patients with hyperprolactinemia.
 The study consists of 16 consecutive patients with high prolactin (PRL) levels (group I) and a control group of 11 normoprolactinemic
 patients (group II). Pituitary tumor tissues of patients in groups I and II were analyzed for immunohistochemical (IHC) expression
 of prolactin and leptin. Group I has significantly higher levels of leptin than group II (P&amp;nbsp;&amp;lt;&amp;nbsp;0.001). There is a strong correlation between PRL and leptin concentrations in group I. However, there were no statistically
 significant diff...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1742026</comments>
            <pubDate>Thu, 28 Aug 2008 15:37:51 +0100</pubDate>
            <guid isPermaLink="false">1742026</guid>        </item>
        <item>
            <title>Recurrent pituitary ependymoma: a complex clinical problem</title>
            <link>http://www.medworm.com/index.php?rid=1713571&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu345gxr378g03tr0%2F</link>
            <description>We present a complex case of a recurrent ependymoma of the parasellar region which has been difficult to clinically manage
 due to its tendency to recurrence. Our patient has had four operations over the last 28&amp;nbsp;years, with external beam radiotherapy,
 but still has residual tumor and is currently panhypopituitary and with significant visual loss. We believe there is considerable
 uncertainty as to the optimal management of any future progression, which seems likely, and are currently considering the
 use of radiosurgery with careful sparing of the optic chiasm, or possibly the chemotherapeutic agent temozolomide. Our case
 emphasises the recurrent nature of this rare but difficult tumor.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0139-xAuthors
		Rosie B...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1713571</comments>
            <pubDate>Fri, 15 Aug 2008 09:06:29 +0100</pubDate>
            <guid isPermaLink="false">1713571</guid>        </item>
        <item>
            <title>Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886)</title>
            <link>http://www.medworm.com/index.php?rid=1688715&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx3m160781445gq2l%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In 1886 Pierre Marie used the term “acromegaly” for the first time and gave a full description of the characteristic clinical
 picture. However several others had already given clear clinical descriptions before him and sometimes had given the disease
 other names. After 1886, it gradually became clear that pituitary enlargement (caused by a pituitary adenoma) was the cause
 and not the consequence of acromegaly, as initially thought. Pituitary adenomas could be found in the great majority of cases.
 It also became clear that acromegaly and gigantism were the same disease but occurring at different stages of life and not
 different diseases as initially thought. At the end of the 19th and beginning of the 20th century most information was derived
 from case descript...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1688715</comments>
            <pubDate>Wed, 06 Aug 2008 05:55:29 +0100</pubDate>
            <guid isPermaLink="false">1688715</guid>        </item>
        <item>
            <title>Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection</title>
            <link>http://www.medworm.com/index.php?rid=1654951&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc24453r251260070%2F</link>
            <description>Conclusion Our study provides strong evidence suggesting that, regardless of initial prolactin level, preoperative dopamine agonist
 therapy is not detrimental. In fact, pretreatment with dopamine agonist drugs, possibly by inducing tumor regression, seemed
 to improve the surgeon’s ability to resect a greater percentage of the tumor and led to better control of the prolactin level.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0135-1Authors
		Michael E. Sughrue, University of California at San Francisco Department of Neurological Surgery San Francisco CA USAEdward F. Chang, University of California at San Francisco Department of Neurological Surgery San Francisco CA USAJ. Blake Tyrell, University of California at San Francisco Department of Medicine San Francisco CA USASandeep K...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1654951</comments>
            <pubDate>Thu, 24 Jul 2008 09:19:05 +0100</pubDate>
            <guid isPermaLink="false">1654951</guid>        </item>
        <item>
            <title>Prevalence of 
 gsp
 oncogene in somatotropinomas and clinically non-functioning pituitary adenomas: our experience</title>
            <link>http://www.medworm.com/index.php?rid=1642132&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl602535t2j442027%2F</link>
            <description>Conclusion We found a lower than expected prevalence of gsp mutations in somatotropinomas and a similar prevalence in NFPA compared to previous studies from other countries.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0136-0Authors
		Giselle Fernandes Taboada, Universidade Federal do Rio de Janeiro (UFRJ) Serviço de Endocrinologia do Hospital Universitário Clementino Fraga Filho Rua Nascimento Silva, 555/101, Ipanema Rio de Janeiro Brazil 22421-020Ana Lúcia Osório Tabet, Universidade Estadual do Rio de Janeiro Serviço de Endocrinologia do Hospital Universitário Pedro Ernesto Rio de Janeiro BrazilLuciana A. Naves, Universidade de Brasília Serviço de Endocrinologia do Hospital Universitário de Brasília Brasília BrazilDenise Pires de Carvalho, Universidade Federal do Rio ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1642132</comments>
            <pubDate>Sat, 19 Jul 2008 13:59:49 +0100</pubDate>
            <guid isPermaLink="false">1642132</guid>        </item>
        <item>
            <title>Craniopharyngioma surgery</title>
            <link>http://www.medworm.com/index.php?rid=1638906&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F436q3320788557n4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ideal surgical treatment of craniopharyngiomas remains a major challenge for neurosurgeons. Craniopharyngiomas grow in the
 deep-seated hypothalamic area that is paramount for vegetative, emotional and endocrine function, and for maintaining worthwhile
 life. The benign histological nature of craniopharyngiomas belies their biological behavior and the propensity to recur is
 a major threat. Surgical treatment has to weigh the risk of hypothalamic damage against the risk of tumor recurrence or progression.
 Both aggressive surgery and conservative minor surgery followed by radiotherapy has been proclaimed by the proponents of different
 schools. During the past decade, the pendulum has swung back to surgery with the attempt at radical removal. Refined neurosurgical
 tech...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1638906</comments>
            <pubDate>Fri, 18 Jul 2008 06:30:24 +0100</pubDate>
            <guid isPermaLink="false">1638906</guid>        </item>
        <item>
            <title>Governor Pio Pico, the monster of California…no more: lessons in neuroendocrinology</title>
            <link>http://www.medworm.com/index.php?rid=1577040&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu7645787h2435373%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We hypothesize that Pio Pico, the last Mexican Governor of California, had acromegaly between at least ages 43 to 57, from
 1844 to 1858, before Pierre Marie published the clinical description of acromegaly in 1886. Pico’s probable growth hormone-secreting
 pituitary tumor likely infarcted spontaneously after 1858. The tumor infarction resulted in burnt-out acromegaly and probably
 restored normal pituitary function. Pearce Bailey published the first account of pituitary tumor infarction only in 1898.
 Pico’s undiagnosed, misunderstood, profoundly acromegalic appearance was widely misinterpreted, leading to pervasive, degrading,
 and highly prejudicial comments. This landmark case study in neuroendocrinology provides the opportunity to re-examine elements
 of 19th c...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1577040</comments>
            <pubDate>Thu, 03 Jul 2008 08:26:56 +0100</pubDate>
            <guid isPermaLink="false">1577040</guid>        </item>
        <item>
            <title>Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas</title>
            <link>http://www.medworm.com/index.php?rid=1575012&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Flj61w07416l634np%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ergot-derived dopamine receptor agonists, especially pergolide and cabergoline, have been associated with an increased risk
 of valvular heart disease in patients treated for Parkinson’s disease. Cabergoline at lower doses than those employed in Parkinson’s
 disease is widely used in patients with prolactinomas, because of its high efficacy and tolerability; however, its safety
 with regard to cardiac valve disease is unknown. In order to assess the prevalence of cardiac valve regurgitation in patients
 with prolactinomas treated with long-term cabergoline, we performed a prospective and multicentric study including four university
 centers in the province of Quebec. A transthoracic echocardiogram was performed in 70 patients with prolactinomas treated
 with cabergo...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1575012</comments>
            <pubDate>Wed, 02 Jul 2008 15:35:00 +0100</pubDate>
            <guid isPermaLink="false">1575012</guid>        </item>
        <item>
            <title>What are critical outcome measures for patients receiving pituitary replacement following brain injury?</title>
            <link>http://www.medworm.com/index.php?rid=1575011&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv24q050q86157082%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;There are scant prospective studies defining improvements in critical outcome measures with hormone replacement in hypopituitarism
 secondary to brain injury. We review the tests of cognition and physical function and summarize their use for subjects that
 are deficient in anterior hormone production during anterior pituitary hormone replacement in brain injury and propose these
 as the minimal tests that are feasible for a physician to perform in a clinical setting. We summarize the studies conducted
 to assess outcome measures after brain injury and also report preliminary findings for improvements in cognition and physical
 function in subjects with brain injury and GH deficiency.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0133-3Authors
		Sorin G. Beca, Un...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1575011</comments>
            <pubDate>Wed, 02 Jul 2008 15:35:00 +0100</pubDate>
            <guid isPermaLink="false">1575011</guid>        </item>
        <item>
            <title>Transient asystole during endoscopic transsphenoidal surgery: an example of trigeminocardiac reflex</title>
            <link>http://www.medworm.com/index.php?rid=1559898&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqjh465g870205308%2F</link>
            <description>Content Type Journal ArticleCategory LetterDOI 10.1007/s11102-008-0132-4Authors
		Bernhard Schaller, University of Paris Departments of Neurosurgery Paris FranceNora Sandu, University of Paris Departments of Neurosurgery Paris FranceGiulia Ottoviani, University of Milano Centro “Lino Rossi” Research Center for the Study and Prevention of the Unexpected Perinatal Death and SIDS, Institute of Pediatrics and Neonatology Milan ItalyAndreas Filis, Erlangen GermanyChristoph Noethen, Erlangen GermanyMichael Buchfelder, Erlangen GermanyFor the Trigemino-Cardiac-Reflex-Examination-Group (T.C.R.E.G.), Paris France
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1559898</comments>
            <pubDate>Sat, 28 Jun 2008 08:11:43 +0100</pubDate>
            <guid isPermaLink="false">1559898</guid>        </item>
        <item>
            <title>Endogenous estradiol may influence IGF-I levels in acromegalic women treated with pegvisomant</title>
            <link>http://www.medworm.com/index.php?rid=1466745&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq5n161142q347717%2F</link>
            <description>We present the case of a 46-year-old woman with acromegaly currently being treated with the growth hormone (GH) receptor antagonist
 pegvisomant showing strongly fluctuating IGF-I levels. We prospectively measured estradiol, IGF-I, IGF-I binding protein,
 acid labile subunit, basal endogenous GH, binding protein and pegvisomant levels for 6&amp;nbsp;months every week. Estradiol levels
 showed a strongly negative correlation with IGF-I (r&amp;nbsp;=&amp;nbsp;−0.733, P&amp;nbsp;&amp;lt;&amp;nbsp;0.001), and less so with ALS (r&amp;nbsp;=&amp;nbsp;−0.433, P&amp;nbsp;&amp;lt;&amp;nbsp;0.05) and IGFBP3 (r&amp;nbsp;=&amp;nbsp;−0.590, P&amp;nbsp;&amp;lt;&amp;nbsp;0.01). Estradiol was not significantly correlated with endogenous GH or pegvisomant levels. Likewise, IGF-I did not correlate
 with endogenous GH or pegvisomant levels. In our patient, endogeno...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1466745</comments>
            <pubDate>Fri, 23 May 2008 05:52:30 +0100</pubDate>
            <guid isPermaLink="false">1466745</guid>        </item>
        <item>
            <title>Pituitary-gonadal axis: historical notes</title>
            <link>http://www.medworm.com/index.php?rid=1463302&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk2221m1223g05715%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Though it was appreciated at a very early time that removal of gonads had evident consequences, the anatomy and function of
 the gonads were essentially unknown in the Antiquity. It was not until around 1600 that men like Vesalius, de Graaf and Leeuwenhoek
 initiated rational studies on the structure and function of the gonads. The close relationship between gonads and hypothalamus/pituitary
 was recognized less than 100&amp;nbsp;years ago. The last pituitary hormone with gonadotroph effect was discovered a generation ago.
 This paper briefly describes some major points in the development of our knowledge of the pituitary-gonadal function. Considering
 the huge number of studies involved, this review reflects but a tiny fraction of the work laid down over millennia within
 ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1463302</comments>
            <pubDate>Wed, 21 May 2008 06:00:52 +0100</pubDate>
            <guid isPermaLink="false">1463302</guid>        </item>
        <item>
            <title>Chapter 1: pathophysiology of hypopituitarism in the setting of brain injury</title>
            <link>http://www.medworm.com/index.php?rid=1448645&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw518152t227l7452%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The complex pathophysiology of traumatic brain injury (TBI) involves not only the primary mechanical event but also secondary
 insults such as hypotension, hypoxia, raised intracranial pressure and changes in cerebral blood flow and metabolism. It is
 increasingly evident that these initial insults as well as transient events and treatments during the early injury phase can
 impact hypothalamic-pituitary function both acutely and chronically after injury. In turn, untreated pituitary hormonal dysfunction
 itself can further hinder recovery from brain injury. Secondary adrenal insufficiency, although typically reversible, occurs
 in up to 50% of intubated TBI victims and is associated with lower systemic blood pressure. Chronic anterior hypopituitarism,
 although reversi...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1448645</comments>
            <pubDate>Thu, 15 May 2008 06:10:38 +0100</pubDate>
            <guid isPermaLink="false">1448645</guid>        </item>
        <item>
            <title>More than a prolactinoma</title>
            <link>http://www.medworm.com/index.php?rid=1445538&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl4520868h68n7558%2F</link>
            <description>Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0129-zAuthors
		Ambar Basu, Christie Hospital Department of Endocrinology Manchester UKGeorg Brabant, Christie Hospital Department of Endocrinology Manchester UKKanna K. Gnanalingham, Salford Royal Hospital Department of Neurosurgery, Greater Manchester Neuroscience Centre Salford Greater Manchester M6 8HD UK
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1445538</comments>
            <pubDate>Tue, 13 May 2008 21:17:43 +0100</pubDate>
            <guid isPermaLink="false">1445538</guid>        </item>
        <item>
            <title>Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study</title>
            <link>http://www.medworm.com/index.php?rid=1425852&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy7xm716362273x23%2F</link>
            <description>Conclusions Our pilot study suggests that decreasing the glucocorticoid replacement dose to ~15&amp;nbsp;mg/day is beneficial in terms of patients’
 body composition, lipid profile and quality of life.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0126-2Authors
		Karina Danilowicz, Hospital de Clínicas Division of Endocrinology Avenida Córdoba 2351, 5° piso, 1120 Ciudad Autónoma de Buenos Aires ArgentinaOscar Domingo Bruno, Hospital de Clínicas Division of Endocrinology Avenida Córdoba 2351, 5° piso, 1120 Ciudad Autónoma de Buenos Aires ArgentinaMarcos Manavela, Hospital de Clínicas Division of Endocrinology Avenida Córdoba 2351, 5° piso, 1120 Ciudad Autónoma de Buenos Aires ArgentinaReynaldo Manuel Gomez, Hospital de Clínicas Division of Endocrinology Avenida Córdoba 2...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1425852</comments>
            <pubDate>Tue, 06 May 2008 16:13:53 +0100</pubDate>
            <guid isPermaLink="false">1425852</guid>        </item>
        <item>
            <title>Utility of [18F] fluoro-2-deoxy-d
 -glucose positron emission tomography in the localization of ectopic ACTH-secreting tumors</title>
            <link>http://www.medworm.com/index.php?rid=1425851&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F876r4417l10v5231%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Ectopically ACTH producing tumors may be difficult to localize by conventional radiology and functional imaging may be helpful.
 Case 1: 31-year-old man was diagnosed with ectopic ACTH-dependent Cushing’s syndrome (ECS). Thorax CT revealed a 1.3&amp;nbsp;cm nodular
 opacity in upper left lobe, suggestive of residual lesion. [18F] fluoro-2-deoxy-d-glucose ([18F] FDG) positron emission tomography ([18F] FDG PET) scan revealed mild glycolytic metabolic activity. Pathological examination confirmed an ACTH-positive carcinoid
 tumor. Case 2: 53-year-old woman presented with very rapid onset ECS. Pituitary MRI was normal. Thorax CT revealed no tumoral
 lesion. Abdominal and pelvic MRI showed images suggestive of hepatic and iliac, femoral and lumbar secondary implants. [18F] FDG...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1425851</comments>
            <pubDate>Tue, 06 May 2008 16:13:53 +0100</pubDate>
            <guid isPermaLink="false">1425851</guid>        </item>
        <item>
            <title>Cushing’s disease: radiation therapy</title>
            <link>http://www.medworm.com/index.php?rid=1401934&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3230lw4701651272%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The usual first treatment for Cushing’s disease is surgical removal of the pituitary adenoma. In patients in whom surgery
 is unsuccessful or who decline an operation, radiation to the pituitary offers the possibility of remission. No form of radiation
 delivery results in immediate control of cortisol production. Thus, until radiation treatment becomes effective, medical therapy
 to lower cortisol production is indicated. The time to remission with radiation therapy cannot be predicted, medical therapy
 should be discontinued every 6&amp;nbsp;months to assess response to radiation treatment; a normal 24&amp;nbsp;h urine free cortisol being the
 optimal outcome. There are no prospective studies comparing the results among the different types of radiation delivery. The
 type o...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1401934</comments>
            <pubDate>Fri, 25 Apr 2008 10:20:13 +0100</pubDate>
            <guid isPermaLink="false">1401934</guid>        </item>
        <item>
            <title>Focal radiation therapy for patients with persistent/recurrent pituitary adenoma, despite previous radiotherapy</title>
            <link>http://www.medworm.com/index.php?rid=1401935&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft28131357386387r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;With the stricter endocrine definitions of cure following conventionally planned and fractionated radiotherapy for functioning
 pituitary adenomas, together with the move in the profession (since the advent of high quality MRI) to postpone radiation
 therapy until macroscopic disease appears after surgery, it is now realised that cure rates following conventional radiotherapy
 approximate three out of four rather than the &amp;gt;90% cited for more than a decade. Patients with persistent active tumours may
 be successfully further treated by focal radiation therapy by one of the stereotactic focal techniques. We have experience
 of such re-treatment radiation therapy in 50 patients. With careful case selection, we here demonstrate that in acromegaly,
 for example, normalisa...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1401935</comments>
            <pubDate>Fri, 25 Apr 2008 10:20:12 +0100</pubDate>
            <guid isPermaLink="false">1401935</guid>        </item>
        <item>
            <title>The GnRH test in the assessment of patients with pituitary and parapituitary lesions: results of a 5-year retrospective study</title>
            <link>http://www.medworm.com/index.php?rid=1388535&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx02w0115v0nn82u7%2F</link>
            <description>Conclusions The data from this study indicate that the GnRH test is unhelpful in the clinical assessment of the HP axis in patients with
 HP disease.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0124-4Authors
		N. K. Chammas, King’s College Hospital Endocrine Unit London SE5 9PJ UKS. M. Chambers, King’s College Hospital Clinical Biochemistry London SE5 9PJ UKP. E. Harris, King’s College Hospital Endocrine Unit London SE5 9PJ UK
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1388535</comments>
            <pubDate>Sat, 19 Apr 2008 14:48:14 +0100</pubDate>
            <guid isPermaLink="false">1388535</guid>        </item>
        <item>
            <title>Growth hormone deficiency in children</title>
            <link>http://www.medworm.com/index.php?rid=1388534&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff2546602038585w3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The foundation for the diagnosis of growth hormone (GH) deficiency in childhood must be auxology, that is, the comparison
 of the child’s growth pattern to that of established norms for gender and ethnicity. It is only in those growing considerably
 more slowly than average that testing for GHD makes sense. Assessment of laboratory tests, whether static, for example, the
 measurement of growth factors or their binding proteins, or dynamic, for example, secretagogue-stimulated GH secretion is
 confirmatory. One must be cognizant of the assay used to determine GH, for there may be a 3-fold difference in the concentration
 of GH among commercially-available assays. Controversy still exists concerning the measurement of spontaneous GH release and
 whether sex-steroid prim...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1388534</comments>
            <pubDate>Sat, 19 Apr 2008 14:48:14 +0100</pubDate>
            <guid isPermaLink="false">1388534</guid>        </item>
        <item>
            <title>Androgen deficiency: effects on body composition</title>
            <link>http://www.medworm.com/index.php?rid=1385617&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F608214826v2q6434%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Published data on the effects of androgen deficiency and testosterone administration on body composition in men and women
 are reviewed. In experimental paradigms, androgen deprivation decreases lean body mass and increases fat mass in men, and
 physiologic replacement reverses these abnormalities. The anabolic effects of testosterone administration on muscle in men
 are well-established, and current understanding of the underlying mechanisms are discussed. Randomized, placebo-controlled
 studies have been performed to investigate the effects of testosterone administration on body composition in a number of male
 hypogonadal states, including HIV-associated weight loss, supraphysiologic glucocorticoid administration, aging and obesity,
 with variable outcomes, and the r...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1385617</comments>
            <pubDate>Fri, 18 Apr 2008 15:01:52 +0100</pubDate>
            <guid isPermaLink="false">1385617</guid>        </item>
        <item>
            <title>Transcranial surgery for pituitary adenomas</title>
            <link>http://www.medworm.com/index.php?rid=1385618&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F50636657p4641372%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Following a century of evolution and refinements in standard surgical techniques, the vast majority of operations for pituitary
 adenoma to date are performed utilizing transsphenoidal approaches. From current large series one obtains the impression that
 certainly less than 10% of these tumors require craniotomies. However, still several tumors, which’s volume is mainly localized
 outside of the sella require transcranial approaches, of which the pterional and subfrontal routes are the most widely used.
 The goal of surgical treatment is rapid eradication of the tumor mass, decompression of visual pathways and elimination of
 hormonal oversecretion whilst preserving the normal gland and avoiding potential surgical complications. Even with microsurgical
 techniques an...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1385618</comments>
            <pubDate>Fri, 18 Apr 2008 15:01:49 +0100</pubDate>
            <guid isPermaLink="false">1385618</guid>        </item>
        <item>
            <title>Inter- and intra-observer variability in detection and progression assessment with MRI of microadenoma in Cushing’s disease patients followed up after bilateral adrenalectomy</title>
            <link>http://www.medworm.com/index.php?rid=1383252&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl7745l1527v2m52v%2F</link>
            <description>Conclusions Pituitary MRI study of patients with Cushing disease treated by adrenalectomy remains difficult. In practice, interpretation
 of MRI studies by a well-experienced reader should be preferred, unless a final decision can be reached by consensus between
 two and several readers.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0123-5Authors
		Hélène Bahurel-Barrera, Cochin Hospital, Faculté René Descartes, Paris 5 University Department of Radiology A Paris FranceGuillaume Assie, Cochin Hospital, Faculté René Descartes, Paris 5 University, Centre de Référence des Maladies Rares de la Surrénale Department of Endocrinology Paris FranceStéphane Silvera, Cochin Hospital, Faculté René Descartes, Paris 5 University Department of Radiology A Paris FranceXavier Bertagna, C...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1383252</comments>
            <pubDate>Thu, 17 Apr 2008 15:11:33 +0100</pubDate>
            <guid isPermaLink="false">1383252</guid>        </item>
        <item>
            <title>Secondary hypoadrenalism</title>
            <link>http://www.medworm.com/index.php?rid=1383253&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F464822064x01r3k5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Secondary adrenal insufficiency (SAI) is a clinical disorder that results from hypothalamic or hypophyseal damage or from
 prolonged administration of supraphysiological doses of glucocorticoids. Since glucocorticoids are widely used for a variety
 of diseases, the prevalence of SAI is by far exceeding that of primary adrenal insufficiency. Although the presentation of
 adrenal insufficiency may be insidious and difficult to recognize, an appropriate adrenocortical hormone replacement could
 lead to a normal quality of life and longevity can be achieved. The spectrum of adrenal insufficiency ranges from overt adrenal
 crises to subtle dysfunctions in asymptomatic patients who may be at risk of developing acute adrenal insufficiency since
 their hypothalamic-pituitary-ad...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1383253</comments>
            <pubDate>Thu, 17 Apr 2008 15:11:32 +0100</pubDate>
            <guid isPermaLink="false">1383253</guid>        </item>
        <item>
            <title>Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=1383254&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu717160725115jm2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In the vast majority of cases, basal serum GH and IGF-1 levels are markedly increased in patients with obvious clinical signs
 and symptoms of acromegaly. The oral glucose tolerance test (OGTT) is useful for diagnosis in the minority of patients who
 have weak GH hypersecretion. The cutoff for a “normal” GH nadir in the OGTT remains to be agreed. The type of GH assay, its
 sensitivity, the type of standard used by the manufacturer, the patient’s age and especially gender, must all be taken into
 account. Recent studies using new highly sensitive assays suggest an upper normal GH nadir of 0.71&amp;nbsp;μg/l for female healthy
 patients, but no “universal” cut-off has yet been defined for healthy males (from 0.057 to 0.25&amp;nbsp;μg/l). The 1&amp;nbsp;μg/l cutoff propos...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1383254</comments>
            <pubDate>Thu, 17 Apr 2008 15:11:31 +0100</pubDate>
            <guid isPermaLink="false">1383254</guid>        </item>
        <item>
            <title>Central hypothyroidism</title>
            <link>http://www.medworm.com/index.php?rid=1380427&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy086126106411415%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Central hypothyroidism (CH) is a rare cause of hypothyroidism due to an insufficient stimulation of an otherwise normal thyroid
 gland and it is caused by either pituitary (secondary hypothyroidism) or hypothalamic (tertiary hypothyroidism) defects. The
 diagnosis of CH is usually suggested by the finding of lowered thyroid hormone concentrations, associated with inappropriately
 low/normal TSH levels. Restoration and maintenance of euthyroidism represent the therapeutic goals in all forms of CH. On
 these basis, the vast majority of patients with CH is treated with standard levo-thyroxine (L-T4) therapy which is tailored
 according to FT4 circulating levels that should be maintained in the normal range.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0122-6Author...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1380427</comments>
            <pubDate>Wed, 16 Apr 2008 14:58:43 +0100</pubDate>
            <guid isPermaLink="false">1380427</guid>        </item>
        <item>
            <title>Transient asystole during endoscopic transsphenoidal surgery for Acromegaly: an example of trigeminocardiac reflex</title>
            <link>http://www.medworm.com/index.php?rid=1368710&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft2mv645202u88706%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cardiac arrhythmias are rare during transsphenoidal surgery and is often secondary to stimulation of the trigeminal nerve
 endings that supply the nasal passages and cavernous sinus walls. Authors report a patient with Acromegaly, who developed
 transient asystole, during the dissection of the adenoma extending into the left cavernous sinus wall. In such cases, the
 use of prophylactic atropine may help to avoid such a complication.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0118-2Authors
		Ahmed H. Abou-Zeid, Hope Hospital Department of Neurosurgery, Greater Manchester Neuroscience Centre Salford, Greater Manchester M6 8HD UKJulian R. E. Davis, University of Manchester School of Medicine, Endocrine Sciences Research Group Manchester UKTar...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368710</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:48 +0100</pubDate>
            <guid isPermaLink="false">1368710</guid>        </item>
        <item>
            <title>Hyperprolactinemia</title>
            <link>http://www.medworm.com/index.php?rid=1368709&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3p2g786330352546%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In several respects prolactin is unique among anterior pituitary hormones. The primary regulation of prolactin secretion is
 mediated through hypothalamic inhibition, and the diagnosis of hyperprolactinemia can be established without the use of stimulation
 or suppression tests. Documenting the presence of hyperprolactinemia is not difficult–the challenge is in identifying the
 cause of the hormone hypersecretion. With immunoradiometric assays falsely low levels of prolactin are occasionally seen in
 patients with macroadenomas and very high serum prolactin (the hook effect). Macroprolactin should be suspected when a patient
 with hyperprolactinemia does not present with typical clinical symptoms, and all hyperprolactinemic sera should be screened
 for macroprolactin....</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368709</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:48 +0100</pubDate>
            <guid isPermaLink="false">1368709</guid>        </item>
        <item>
            <title>Diagnosis of adult GH deficiency</title>
            <link>http://www.medworm.com/index.php?rid=1368712&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa1134j360k42413n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Based on previous consensus statements, it has been widely accepted that the diagnosis of adult growth hormone deficiency
 (GHD) must be shown biochemically by provocative tests of GH secretion; in fact, the measurement of IGF-I as well as of other
 markers was considered unable to distinguish between normal and GHD subjects. The Insulin Tolerance Test (ITT) was indicated
 as that of choice and severe GHD defined by a GH peak lower than 3&amp;nbsp;μg/l. It is now recognized that, although normal IGF-I
 levels do not rule out severe GHD, very low IGF-I levels in patients highly suspected for GHD (i.e. patients with childhood-onset
 severe GHD or with multiple hypopituitarism acquired in adulthood) can be considered as definite evidence for severe GHD.
 However, patients sus...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368712</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:47 +0100</pubDate>
            <guid isPermaLink="false">1368712</guid>        </item>
        <item>
            <title>Female hypogonadism: evaluation of the hypothalamic–pituitary–ovarian axis</title>
            <link>http://www.medworm.com/index.php?rid=1368711&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj5n2023nx3t54p85%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Female hypogonadism refers to deficient or abnormal function of the hypothalamic–pituitary–ovarian axis that clinically presents
 with menstrual cycle disturbances. Female hypogonadism can be due to a congenital or acquired cause, and the defect can be
 at the level of the hypothalamus, pituitary or ovary. A careful history, physical exam and selected laboratory testing can
 often determine the locus of the defect and whether it results from a structural or hormonal problem. Laboratory testing generally relies on basal hormone levels; however, timing of blood sampling in relation to menses is important
 to interpretation of the data.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0109-3Authors
		Micol S. Rothman, University of Colorado at Denver and Health Sc...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368711</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:47 +0100</pubDate>
            <guid isPermaLink="false">1368711</guid>        </item>
        <item>
            <title>Male hypogonadism</title>
            <link>http://www.medworm.com/index.php?rid=1368713&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F24g68pk70384j635%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The hypothalamic–pituitary–gonadal (HPG) axis regulates the development, endocrine and reproductive function of the gonads
 throughout all phases of life. Male hypogonadism is defined an inadequate gonadal function, as manifested by deficiency in
 gametogenesis and/or secretion of gonadal hormones. In most cases, male hypogonadism is diagnosed through detailed history,
 physical examination and a few basic hormonal evaluations. In selected cases, however, additional tests are needed to define
 the aetiology and the extent of HPG axis dysfunction. These include semen analysis, pituitary imaging studies, genetic studies,
 bone densitometry, testicular ultrasonography, testicular biopsy and hormonal dynamic testing. The stimulation tests of the
 HPG are of particular i...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368713</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:46 +0100</pubDate>
            <guid isPermaLink="false">1368713</guid>        </item>
        <item>
            <title>Drugs and HPA axis</title>
            <link>http://www.medworm.com/index.php?rid=1368715&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh6v3535136u66820%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper outlines the interferences of the most widely used drugs with hypothalamo-pituitary-adrenal function and the related
 laboratory parameters, with the purpose of providing practical help to clinicians during testing for hypo- or hypercortisolemic
 states.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0114-6Authors
		Alberto Giacinto Ambrogio, University of Milan Istituto Auxologico Italiano, Ospedale San Luca, IRCCS via Spagnoletto 3 20149 Milan ItalyFrancesca Pecori Giraldi, University of Milan Istituto Auxologico Italiano, Ospedale San Luca, IRCCS via Spagnoletto 3 20149 Milan ItalyFrancesco Cavagnini, University of Milan Istituto Auxologico Italiano, Ospedale San Luca, IRCCS via Spagnoletto 3 20149 Milan Italy
	

	
		Journal PituitaryOnline ISSN 157...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368715</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:45 +0100</pubDate>
            <guid isPermaLink="false">1368715</guid>        </item>
        <item>
            <title>Does the type and severity of brain injury predict hypothalamo–pituitary dysfunction? Does post-traumatic hypopituitarism predict worse outcome?</title>
            <link>http://www.medworm.com/index.php?rid=1368714&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Frh6121727u8jl246%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Several studies have reported a close association between traumatic brain injury (TBI) and pituitary dysfunction, and expert
 panels have recently proposed recommendations for hormone assessment and replacement for pituitary insufficiency after TBI.
 Given the high incidence of TBI, identification of reliable predictors is of utmost importance in order to secure a cost-effective
 screening strategy. It has not yet been possible to identify early hormone alterations as a useful tool for the prediction
 of long-term post-traumatic hypopituitarism, whereas indicators of increased trauma severity have been reported as predictive
 in an increasing number of studies. Outcome studies have moreover indicated that post-traumatic hypopituitarism is of clinical
 significance, whic...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368714</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:45 +0100</pubDate>
            <guid isPermaLink="false">1368714</guid>        </item>
        <item>
            <title>Drugs and prolactin</title>
            <link>http://www.medworm.com/index.php?rid=1368716&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9428w1347757k050%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Medications commonly cause hyperprolactinemia and their use must be differentiated from pathologic causes. The most common
 medications to cause hyperprolactinemia are the antipsychotic agents, although some of the newer atypical antipsychotics do
 not do so. Other medications causing hyperprolactinemia include antidepressants, antihypertensive agents, and drugs which
 increase bowel motility. Often, the medication-induced hyperprolactinemia is symptomatic, causing galactorrhea, menstrual
 disturbance, and erectile dysfunction. In the individual patient, it is important differentiate hyperprolactinemia due to
 a medication from a structural lesion in the hypothalamic–pituitary area. This can be done by stopping the medication temporarily
 to determine if the prolactin...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368716</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:44 +0100</pubDate>
            <guid isPermaLink="false">1368716</guid>        </item>
        <item>
            <title>Systemic illness</title>
            <link>http://www.medworm.com/index.php?rid=1368717&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1104810tlm23k556%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Systemic illnesses are associated with alterations in the hypothalamic–pituitary–peripheral hormone axes, which represent
 part of the adaptive response to stressful events and may be influenced by type and severity of illness and/or pharmacological
 therapy. The pituitary gland responds to an acute stressful event with two secretory patterns: adrenocorticotropin (ACTH),
 prolactin (PRL) and growth hormone (GH) levels increase, while luteinizing hormone (LH), follicle-stimulating hormone (FSH)
 and thyrotropin (TSH) levels may either decrease or remain unchanged, associated with a decreased activity of their target
 organ. In protracted critical illness, there is a uniformly reduced pulsatile secretion of ACTH, TSH, LH, PRL and GH, causing
 a reduction in serum leve...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1368717</comments>
            <pubDate>Fri, 11 Apr 2008 06:15:43 +0100</pubDate>
            <guid isPermaLink="false">1368717</guid>        </item>
        <item>
            <title>Lymphocytic hypophysitis with associated thyroiditis in a man with aseptic meningitis</title>
            <link>http://www.medworm.com/index.php?rid=1366435&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1155403q63135622%2F</link>
            <description>Conclusions Based on clinical and radiological grounds, the diagnosis was consistent with lymphocytic hypophysitis associated with subacute
 thyroiditis. This is only the second report of this combination in the absence of autoimmunity and the first report of LH
 and thyroiditis with associated aseptic meningitis in the absence of tissue autoantibodies. We propose a possible viral illness
 as the unifying aetiological cause
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0119-1Authors
		Sarina Lim, Waikato Hospital Department of Endocrinology Hamilton New ZealandMarianne S. Elston, Royal North Shore Hospital Cancer Genetics Unit, Kolling Institute of Medical Research Sydney AustraliaMichael J. Swarbrick, Waikato Hospital Radiology Department Hamilton New ZealandJo...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1366435</comments>
            <pubDate>Thu, 10 Apr 2008 07:07:09 +0100</pubDate>
            <guid isPermaLink="false">1366435</guid>        </item>
        <item>
            <title>Radiotherapy of other sellar lesions</title>
            <link>http://www.medworm.com/index.php?rid=1358288&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5116438877658261%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Radiotherapy has been used as primary or adjuvant treatment in a number of non-adenomatous masses arising from within the
 sella. It is particularly important in the therapeutic algorithm of craniopharyngiomas and meningiomas and has also been used
 in chordomas/chordosarcomas and less commonly, in other lesions. This review describes the place of irradiation in the management
 of these masses.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0116-4Authors
		N. Karavitaki, Churchill Hospital Department of Endocrinology, Oxford Centre for Diabetes, Endocrinology and Metabolism Old Rd, Headington Oxford OX3 7LJ UK
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1358288</comments>
            <pubDate>Fri, 04 Apr 2008 16:53:24 +0100</pubDate>
            <guid isPermaLink="false">1358288</guid>        </item>
        <item>
            <title>Transitioning of children with GH deficiency to adult dosing: changes in body composition</title>
            <link>http://www.medworm.com/index.php?rid=1339914&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh1517620h6486681%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;As more evidence gathers regarding the beneficial effect of growth hormone replacement therapy (GHRT) on body composition
 and other parameters in adults with childhood-onset growth hormone deficiency (GHD), questions emerge regarding whether or
 not GHRT should be discontinued following cessation of statural growth, and the effect of GHRT during the transition period
 on body composition and related parameters. This review discusses the effect of discontinuation of GHRT following attainment
 of adult stature, and the treatment and dose effect when GHRT is reinstated. We also review data regarding who should receive
 GHRT, the criteria for diagnosing persistent GHD, dosing of GHRT and the possibility of a GH ‘holiday’.
 
	Content Type Journal ArticleDOI 10.1007/s111...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1339914</comments>
            <pubDate>Sat, 29 Mar 2008 09:00:55 +0100</pubDate>
            <guid isPermaLink="false">1339914</guid>        </item>
        <item>
            <title>Pituitary testing: a reappraisal</title>
            <link>http://www.medworm.com/index.php?rid=1336120&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F382808v0g37l5085%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
	Content Type Journal ArticleDOI 10.1007/s11102-008-0103-9Authors
		Andrea Giustina, University of Brescia Department of Medical and Surgical Sciences Brescia Italy
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1336120</comments>
            <pubDate>Fri, 28 Mar 2008 08:51:06 +0100</pubDate>
            <guid isPermaLink="false">1336120</guid>        </item>
        <item>
            <title>Transsphenoidal surgery</title>
            <link>http://www.medworm.com/index.php?rid=1336119&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb4m07781hkp32531%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Transsphenoidal surgery has evolved much over nearly 100&amp;nbsp;years. Initially operations were performed often without any input
 from endocrinology colleagues, and without preoperative imaging, operative magnification and illumination. Advances in the
 understanding of the biology of pituitary tumours, close co-operation between endocrinologists, surgeons and oncologists,
 and huge advances in imaging and surgical techniques have led to the evolution of the current transsphenoidal operation to
 the pituitary fossa to the point where a ‘cure’ is often possible with low complication rates. The indications, contraindications
 of transsphenoidal surgery will be discussed, together with nature of the surgical approach and how it can be applied to particular
 pituitary t...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1336119</comments>
            <pubDate>Fri, 28 Mar 2008 08:51:06 +0100</pubDate>
            <guid isPermaLink="false">1336119</guid>        </item>
        <item>
            <title>Alterations in body composition in acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=1336121&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fth003102r1563971%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Acromegaly is a condition characterized by growth hormone (GH) and insulin-like growth factor-1 (IGF-1) hypersecretion, and
 is associated with boney overgrowth, and soft tissue abnormalities due to anabolic, lipolytic, and sodium retaining actions
 of GH. GH and IGF-1 excess is associated with alterations in body composition, including an increase in body water and lean
 body mass, and a reduction in body fat. Achievement of biochemical control of the disease results in a reduction in body water
 and fat-free mass, and an increase in body fat. BMD is generally increased in acromegaly, though the anabolic effect of GH
 excess on bone is reduced, if not negated, by the presence of hypogonadism, particularly with regard to the trabecular compartment.
 Further studies are ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1336121</comments>
            <pubDate>Fri, 28 Mar 2008 08:51:02 +0100</pubDate>
            <guid isPermaLink="false">1336121</guid>        </item>
        <item>
            <title>Modification of hormonal secretion in clinically silent pituitary adenomas</title>
            <link>http://www.medworm.com/index.php?rid=1317445&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa88535417745653g%2F</link>
            <description>Conclusions These two cases, one somatotroph and one thyrotroph adenoma, are an illustration that clinically silent pituitary adenomas
 may in rare circumstances evolve over time and become active, as previously demonstrated in silent corticotroph adenomas.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0085-7Authors
		Tania Daems, University Hospital Antwerp Department of Endocrinology Wilrijkstraat 10 2650 Edegem BelgiumJohan Verhelst, Middelheim Hospital Antwerp Department of Endocrinology Antwerp BelgiumAlex Michotte, University Hospital Vrije Universiteit Brussel Department of Pathology Brussel BelgiumPascale Abrams, University Hospital Antwerp Department of Endocrinology Wilrijkstraat 10 2650 Edegem BelgiumDirk De Ridder, University Hospital Antwerp Departm...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1317445</comments>
            <pubDate>Wed, 19 Mar 2008 11:13:40 +0100</pubDate>
            <guid isPermaLink="false">1317445</guid>        </item>
        <item>
            <title>The evolution of extracranial approaches to the pituitary and anterior skull base</title>
            <link>http://www.medworm.com/index.php?rid=1307536&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F968002728jh23264%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The development of extracranial approaches to the anterior skull base has been a process in development for over a 100&amp;nbsp;years.
 Many neurosurgical (and non-neurosurgical) pioneers have contributed to its evolution. In this paper, we will review the major
 contributors and contributions to this evolving field.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0095-5Authors
		Ashley E. Grosvenor, Stanford University Department of Neurosurgery 300 Pasteur Dr. Stanford CA 94305 USAEdward R. Laws, Stanford University Department of Neurosurgery 300 Pasteur Dr. Stanford CA 94305 USA
	

	
		Journal PituitaryOnline ISSN 1573-7403Print ISSN 1386-341X (Source: Pituitary)</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1307536</comments>
            <pubDate>Fri, 14 Mar 2008 07:01:03 +0100</pubDate>
            <guid isPermaLink="false">1307536</guid>        </item>
        <item>
            <title>The effects of hyperprolactinemia on bone and fat</title>
            <link>http://www.medworm.com/index.php?rid=1304481&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe31wh8020l0t6675%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Many patients with prolactin secreting pituitary tumors have decreased bone mineral. The bone loss is associated with an increase
 in bone resorption and is secondary to prolactin-induced hypogonadism. In both sexes trabecular bone in the spine and hip
 is more affected than cortical bone in the distal radius. Normalization of prolactin and restoration of gonadal function increases
 bone density but is not associated with normalization of bone mass. It is not known whether the bone loss in hyperprolactinemic
 subjects represents a failure to achieve peak bone mass or is due to accelerated bone loss. Despite low bone density hyperprolactinemic
 subjects do not demonstrate increased fractures. The association between prolactin, weight gain and obesity suggests that
 prola...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1304481</comments>
            <pubDate>Thu, 13 Mar 2008 07:06:16 +0100</pubDate>
            <guid isPermaLink="false">1304481</guid>        </item>
        <item>
            <title>Preoperative assessment for pituitary surgery</title>
            <link>http://www.medworm.com/index.php?rid=1304482&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fwpv326354u347605%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Evaluation of pituitary function is essential before pituitary surgery. In hyperprolactinaemic patients with a pituitary macrolesion,
 tumoral secretion of prolactin must be distinguished from ‘disconnection’ hyperprolactinaemia; serum prolactin &amp;gt;200&amp;nbsp;mcg/l
 is virtually diagnostic of a macroprolactinoma whereas levels &amp;lt;80&amp;nbsp;mcg/l usually indicate ‘disconnection’. The prolactin ‘hook
 effect’ should be excluded. A minimum set of pre-operative endocrine tests should include serum electrolytes, cortisol (at
 08.00–09.00&amp;nbsp;h), free-T4, TSH, prolactin, oestradiol/testosterone, LH, FSH and IGF-1. Some clinicians will choose to perform
 pre-operative Synacthen or insulin tolerance testing to further define ACTH reserve. If basal cortisol, Synacth...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1304482</comments>
            <pubDate>Thu, 13 Mar 2008 07:06:15 +0100</pubDate>
            <guid isPermaLink="false">1304482</guid>        </item>
        <item>
            <title>Review of physiology, clinical manifestations, and management of hypothalamic obesity in humans</title>
            <link>http://www.medworm.com/index.php?rid=1289619&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0526878776904823%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hypothalamic injury from acquired structural damage due to infiltrative disease, tumor, or their treatment aftereffects frequently
 results in the development of an obesity syndrome characterized by a rapid, unrelenting weight gain that may be accompanied
 by severe hyperphagia. Weight gain occurs from the disruption of the normal homeostatic functioning of the hypothalamic centers
 responsible for controlling satiety and hunger and regulating energy balance with resulting hyperphagia, autonomic imbalance,
 reduction of energy expenditure, and hyperinsulinemia. Curtailment of weight increase has traditionally been refractory to
 usual dietary and lifestyle interventions. Pharmacotherapy targeting insulin secretion and augmenting sympathetic output have
 been attempted t...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1289619</comments>
            <pubDate>Sat, 08 Mar 2008 10:07:43 +0100</pubDate>
            <guid isPermaLink="false">1289619</guid>        </item>
        <item>
            <title>The pituitary–adrenal axis and body composition</title>
            <link>http://www.medworm.com/index.php?rid=1289620&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr717q01j36g41228%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The activity of the pituitary–adrenal axis can profoundly impact on body composition. This is dramatically seen in Cushing’s
 syndrome (CS) but changes in body composition are also implicated in depression and alcoholic pseudocushing’s. The pathophysiological
 mechanisms underlying these changes remain poorly understood. Changes to body composition in CS include increased fat mass,
 decreased bone mass, thinning of the skin and reduced lean mass. Why these tissues are affected so dramatically is unclear.
 Additionally, the change in body composition between individuals varies considerably for reasons which are only now becoming
 evident. This paper reviews the phenotypic changes with altered pituitary–adrenal axis activity and discusses the mechanisms
 involved....</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1289620</comments>
            <pubDate>Fri, 07 Mar 2008 06:58:30 +0100</pubDate>
            <guid isPermaLink="false">1289620</guid>        </item>
        <item>
            <title>Cushing’s syndrome due to ectopic ACTH production by (neuroendocrine) prostate carcinoma</title>
            <link>http://www.medworm.com/index.php?rid=1287208&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk40l723790j12546%2F</link>
            <description>We report the case of a 62-year-old
 man with CS due to ectopic ACTH production by small cell carcinoma of the prostate. He presented with severe hypercortisolism
 and associated symptoms. Plasma neuron specific enolase (NSE) was grossly elevated. Despite performing a laparoscopic bilateral
 adrenalectomy, the patient died as a result of sepsis with multi-organ failure. Post-mortem immunohistochemical staining of
 prostate tumor tissue showed ACTH expression. ACTH staining was also performed in four additional patients with small cell
 carcinoma of the urinary tract without CS. None of these additional cases showed a positive staining for ACTH. Although a
 rare cause of ectopic ACTH production, neuroendocrine prostate carcinoma should be considered in male patients with Cushing’s
 syndro...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1287208</comments>
            <pubDate>Thu, 06 Mar 2008 16:50:17 +0100</pubDate>
            <guid isPermaLink="false">1287208</guid>        </item>
        <item>
            <title>A rare case of paraganglioma of the sella with bone metastases</title>
            <link>http://www.medworm.com/index.php?rid=1284512&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr2lk6066x6435604%2F</link>
            <description>We present a further
 case of sellar paraganglioma. The patient is a 17-year-old man who developed headache, visual blurring, and diplopia. MRI
 showed a sellar lesion. Trans-nasal trans-sphenoid biopsy showed features of paraganglioma. He was treated by Stereotactic
 radiotherapy. Four months after treatment he developed bone metastases which was palliated by radiation, zoledronic acid,
 and chemotherapy. This is the first case of sellar paraganglioma showing metastases to bone.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-008-0099-1Authors
		K. P. Haresh, All India Institute of Medical Sciences Department of Radiotherapy and Oncology Ansari Nagar New Delhi 110 029 IndiaR. Prabhakar, All India Institute of Medical Sciences Department of Radiotherapy and Oncology A...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1284512</comments>
            <pubDate>Wed, 05 Mar 2008 07:58:39 +0100</pubDate>
            <guid isPermaLink="false">1284512</guid>        </item>
        <item>
            <title>Postoperative assessment of the patient after transsphenoidal pituitary surgery</title>
            <link>http://www.medworm.com/index.php?rid=1284513&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh674vm04613761x1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;While most transsphenoidal pituitary surgery is accomplished without complication, monitoring is required postoperatively
 for a set of disorders that are specific to this surgery. Postoperative assessments are tailored to the early and later postoperative
 periods. In the early period, which spans the first few weeks after surgery, both monitoring of anterior and posterior pituitary
 function and managing neurosurgical issues are the focus of care. Potential disruption of pituitary-adrenal function is covered
 with perioperative glucocorticoids. Various strategies exist for ensuring the integrity of this axis, but typically this is
 done by measuring a morning cortisol on the 2nd or 3rd postoperative days. Patients with levels &amp;lt;10&amp;nbsp;μg/l should continue therapy
...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1284513</comments>
            <pubDate>Wed, 05 Mar 2008 07:58:38 +0100</pubDate>
            <guid isPermaLink="false">1284513</guid>        </item>
        <item>
            <title>Radiotherapy of nonfunctioning and gonadotroph adenomas</title>
            <link>http://www.medworm.com/index.php?rid=1249970&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg226283253702986%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Transsphenoidal surgery is the treatment of choice for NFPA but is seldom curative. The management of patients in whom residual
 tumor is detected after surgery is not clear-cut. Radiation therapy is effective in controlling tumor mass in the majority
 of patients, but is associated with long term complications that call for restriction of its use to patients at high risk
 for tumor growth. New radiation techniques may prove to be safer while retaining the effectiveness of conventional radiotherapy,
 however longer follow-up is necessary to confirm this assumption. For now, it appears to be safe to withhold radiation and
 carefully follow patients with small tumor remnants, whereas large remnants from invasive tumors should be considered for
 radiotherapy. Nevertheless,...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1249970</comments>
            <pubDate>Wed, 20 Feb 2008 16:04:00 +0100</pubDate>
            <guid isPermaLink="false">1249970</guid>        </item>
        <item>
            <title>Endoscopic pituitary surgery</title>
            <link>http://www.medworm.com/index.php?rid=1249969&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8767577252856882%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pituitary surgery is a continuous evolving speciality of the neurosurgeons’ armamentarium, which requires precise anatomical
 knowledge, technical skills and integrated appreciation of the pituitary pathophysiology. What we consider “pure” endoscopic
 transsphenoidal surgery is a procedure performed through the nose and the sphenoid bone, with the endoscope alone throughout
 the whole approach to visualize the surgical target area and without the use of any transsphenoidal retractor. It offers some
 advantages due to the endoscope itself: a superior close-up view of the relevant anatomy and an enlarged working angle are
 provided with an increased panoramic vision inside the surgical area. Concerning results in terms of mass removal, relief
 of clinical symptoms, ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1249969</comments>
            <pubDate>Wed, 20 Feb 2008 16:03:59 +0100</pubDate>
            <guid isPermaLink="false">1249969</guid>        </item>
        <item>
            <title>Quality of life in women with microprolactinoma treated with dopamine agonists</title>
            <link>http://www.medworm.com/index.php?rid=1231668&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft71717j641762m68%2F</link>
            <description>Conclusions QOL is impaired in women with microprolactinoma treated with dopamine agonists, and was inversely associated with the PRL
 levels. This latter finding reinforces the importance of providing adequate disease control for these patients in order to
 avoid the adverse consequences of hyperprolactinemia on QOL.
 
	Content Type Journal ArticleDOI 10.1007/s11102-008-0091-9Authors
		Erika Cesar de Oliveira Naliato, Federal University of Rio de Janeiro (UFRJ), Hyperprolactinemia Unit, Clementino Fraga Filho University Hospital (HUCFF) Division of Endocrinology, Department of Internal Medicine Rio de Janeiro BrazilAlice Helena Dutra Violante, Federal University of Rio de Janeiro (UFRJ), Hyperprolactinemia Unit, Clementino Fraga Filho University Hospital (HUCFF) Division of Endocrinology,...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1231668</comments>
            <pubDate>Wed, 13 Feb 2008 16:12:40 +0100</pubDate>
            <guid isPermaLink="false">1231668</guid>        </item>
        <item>
            <title>Hypopituitarism following radiotherapy</title>
            <link>http://www.medworm.com/index.php?rid=1231667&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb186630g797r0032%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Deficiencies in anterior pituitary hormones secretion ranging from subtle to complete occur following radiation damage to
 the hypothalamic–pituitary (h–p) axis, the severity and frequency of which correlate with the total radiation dose delivered
 to the h–p axis and the length of follow up. Selective radiosensitivity of the neuroendocrine axes, with the GH axis being
 the most vulnerable, accounts for the high frequency of GH deficiency, which usually occurs in isolation following irradiation
 of the h–p axis with doses less than 30&amp;nbsp;Gy. With higher radiation doses (30–50&amp;nbsp;Gy), however, the frequency of GH insufficiency
 substantially increases and can be as high as 50–100%. Compensatory hyperstimulation of a partially damaged h–p axis may restor...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1231667</comments>
            <pubDate>Wed, 13 Feb 2008 16:12:40 +0100</pubDate>
            <guid isPermaLink="false">1231667</guid>        </item>
        <item>
            <title>All patients with ‘idiopathic’ hypopituitarism should be screened for hemochromatosis</title>
            <link>http://www.medworm.com/index.php?rid=1231666&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk6352mt381l51k62%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Hypopituitarism usually occurs as the result of a pituitary tumour or as a consequence of its treatment. If, however, pituitary
 imaging is negative then an alternative diagnosis should be sought. Patients are often diagnosed as having idiopathic hypopituitarism
 when imaging is normal. Our objective is to highlight the importance of screening for hemochromatosis in patients with presumed
 ‘idiopathic’ hypopituitarism. Our patients presented initially with biochemical hypopituitarism and, after initial investigation
 and normal imaging, were labelled as having idiopathic disease. They subsequently developed iron overload in cardiac and hepatic
 tissue respectively requiring regular venesection to deplete body stores. Genetic analysis revealed homozygosity for the C2...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1231666</comments>
            <pubDate>Wed, 13 Feb 2008 16:12:40 +0100</pubDate>
            <guid isPermaLink="false">1231666</guid>        </item>
        <item>
            <title>GH/GHRH axis in HIV lipodystrophy</title>
            <link>http://www.medworm.com/index.php?rid=1231665&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F318146154l1g2h10%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Approximately half of patients with HIV-infection develop abnormal body fat distribution, characterized by increased abdominal,
 breast, and dorsocervical adiposity and decreased fat in the limbs and face in association with antiretroviral therapy. Changes
 in fat distribution are associated with dyslipidemia, insulin resistance, and increased cardiovascular risk in patients with
 HIV lipodystrophy. Growth hormone secretion is reduced and responses to standardized stimulation testing altered, suggesting
 relative growth hormone deficiency in this population. Growth hormone secretion is characterized by normal pulse frequency,
 but decreased pulse amplitude, pulse width, and trough GH levels compared to weight matched, non-HIV-infected patients. Abnormalities
 in GH secr...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1231665</comments>
            <pubDate>Wed, 13 Feb 2008 16:12:40 +0100</pubDate>
            <guid isPermaLink="false">1231665</guid>        </item>
        <item>
            <title>Primary central nervous system lymphoma mimicking pituitary apoplexy: case report</title>
            <link>http://www.medworm.com/index.php?rid=1172482&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F106n7w35rj0014um%2F</link>
            <description>We present
 a case of primary central nervous system (CNS) large B cell lymphoma that manifested as pituitary apoplexy. A 45-year-old
 woman presented with headache, and then rapidly developed a third nerve palsy and bitemporal hemianopsia. Imaging suggested
 a pituitary macroadenoma, with spontaneous necrosis, extending into the suprasellar region, compressing the optic chiasm and
 invading the right cavernous sinus. The patient underwent transsphenoidal resection which revealed a vascular, firm tumor.
 An aggressive decompression of the optic chiasm was performed with complete resolution of both visual fields and third nerve
 palsy. Final pathology showed B cell lymphoma. Systemic work-up including bone marrow aspiration and CSF studies showed no
 other foci of lymphoma, and the patient ...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1172482</comments>
            <pubDate>Mon, 21 Jan 2008 16:12:01 +0100</pubDate>
            <guid isPermaLink="false">1172482</guid>        </item>
        <item>
            <title>Molecular pathogenesis of human prolactinomas identified by gene expression profiling, RT-qPCR, and proteomic analyses</title>
            <link>http://www.medworm.com/index.php?rid=1145474&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa8128232p14847t2%2F</link>
            <description>We examined six prolactinomas and eight normal pituitary glands using oligonucleotide
 GeneChip microarrays, reverse transcription-real time quantitative polymerase chain reaction using 10 prolactinomas, and proteomic
 analysis to examine protein expression in four prolactinomas. Microarray analyses identified 726 unique genes that were statistically
 significantly different between prolactinomas and normal glands, whereas proteomic analysis identified four differently up-regulated
 and 19 down-regulated proteins. Several components of the Notch pathway were altered in prolactinomas, and there was an increased
 expression of the Pit-1 transcription factor, and the survival factor BAG1 but decreased E-cadherin and N-cadherin expression.
 Taken together, expression profiling and proteomic an...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1145474</comments>
            <pubDate>Wed, 09 Jan 2008 16:07:50 +0100</pubDate>
            <guid isPermaLink="false">1145474</guid>        </item>
        <item>
            <title>A primary sellar esthesioneuroblastomas with unusual presentations: a case report and reviews of literatures</title>
            <link>http://www.medworm.com/index.php?rid=1139369&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx01t15015301675n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The development of an esthesioneuroblastoma outside to the region in which olfactory epithelium exists is extremely rare.
 Only nine cases were reported in the previous literatures. The author presents a 40 years-old man with ectopic esthesioneuroblastoma
 in sella turcica. In contrast to the previous nine cases, our case presented unusual presentations—CSF rhinorrhea and meningitis.
 Endoscopic transphenoid approach with removal of tumor and repair of dura defect followed by radiotherapy offered a good result
 in this case. Moreover, differential diagnosis and the origin of the ectopic esthsioneuroblastoma would be discussed.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-007-0081-3Authors
		Jiann-Her Lin, Tri-Service General Hospital Departmen...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1139369</comments>
            <pubDate>Sun, 06 Jan 2008 14:57:00 +0100</pubDate>
            <guid isPermaLink="false">1139369</guid>        </item>
        <item>
            <title>Malignant pituitary corticotroph adenomas: report of two cases and a comprehensive review of the literature</title>
            <link>http://www.medworm.com/index.php?rid=1139368&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe7012814v8823g26%2F</link>
            <description>In conclusion, frequent
 relapses of Cushing’s disease, aggressive growth of macroadenoma, Nelson’s syndrome after adrenalectomy or persistently high
 ACTH levels should prompt the clinician to consider the possibility of pituitary corticotroph carcinomas.
 
	Content Type Journal ArticleCategory Case ReportDOI 10.1007/s11102-007-0080-4Authors
		Agatha A. van der Klaauw, Leiden University Medical Center Department of Endocrinology and Metabolism, C4-R P.O. Box 9600 2300 RC Leiden The NetherlandsTina Kienitz, Charité University Medicine Campus Mitte Clinical Endocrinology, Department of Internal Medicine, Gastroenterology, Hepatology and Endocrinology Berlin GermanyChristian J. Strasburger, Charité University Medicine Campus Mitte Clinical Endocrinology, Department of Internal Medicine...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1139368</comments>
            <pubDate>Sun, 06 Jan 2008 14:56:59 +0100</pubDate>
            <guid isPermaLink="false">1139368</guid>        </item>
        <item>
            <title>Radiotherapy and radiosurgery in acromegaly</title>
            <link>http://www.medworm.com/index.php?rid=1139371&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh85r51rgl6w61443%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Growth-hormone hypersecretion, acromegaly, is associated with reduced life expectancy. First line treatment remains surgery,
 but remission rates vary between 50% and 90%. In case of lack of surgical remission or recurrence, somatostatin agonists can
 be proposed. However, about 30% of patients are partially or totally resistant to this treatment. The growth hormone receptor
 antagonist pegvisomant currently needs more prolonged follow-up studies. Conventional radiotherapy and radiosurgery are two
 radiation treatment modalities that can be proposed to these resistant patients. Reported rates of remission for conventional
 radiotherapy range between 50% and 60% in patients with acromegaly, with a time to remission delayed by several years, and
 adverse effects including...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1139371</comments>
            <pubDate>Fri, 04 Jan 2008 19:51:05 +0100</pubDate>
            <guid isPermaLink="false">1139371</guid>        </item>
        <item>
            <title>Mortality following pituitary radiotherapy</title>
            <link>http://www.medworm.com/index.php?rid=1139370&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F93267143k5h56rt8%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;External beam radiotherapy has been used in the management of pituitary adenomas for nearly a century, preventing tumor regrowth
 following surgery for non-functioning pituitary adenomas and suppressing functional hypersecretion in those which are hormonally
 active. However, it has been linked with a number of potentially significant complications including formation of secondary
 intracranial tumors, cognitive impairment, hypopituitarism and cerebrovascular disease, as well as increased mortality.
 
 Radiation may cause a variety of vascular injuries and hemodynamic changes to the cerebral vasculature, and several authors
 have reported cerebrovascular complications and an increase in cerebrovascular mortality in patients receiving radiotherapy
 for pituitary and othe...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1139370</comments>
            <pubDate>Fri, 04 Jan 2008 19:51:05 +0100</pubDate>
            <guid isPermaLink="false">1139370</guid>        </item>
        <item>
            <title>Expression of p16INK4A gene in human pituitary tumours</title>
            <link>http://www.medworm.com/index.php?rid=1079291&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft2477758777t5788%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Pituitary adenomas comprise 10–15% of primary intracranial tumours but the mechanisms leading to tumour development are yet
 to be clearly established. The retinoblastoma pathway, which regulates the progression through the cell cycle, is often deregulated
 in different types of tumours. We studied the cyclin-dependent kinase inhibitor p16INK4A gene expression at mRNA level in human pituitary adenomas. Forty-six tumour specimens of different subtypes, 21 clinically
 non-functioning, 12 growth hormone-secreting, 6 prolactin-secreting, 6 adrenocorticotropin-secreting, and 1 thyrotropin-secreting
 tumours were studied. All clinically non-functioning and most of the hormone-secreting tumours were macroadenomas (38/46).
 The RT–PCR assay and electrophoresis of the PCR-pr...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1079291</comments>
            <pubDate>Thu, 06 Dec 2007 16:30:40 +0100</pubDate>
            <guid isPermaLink="false">1079291</guid>        </item>
        <item>
            <title>Triple jeopardy in the pituitary</title>
            <link>http://www.medworm.com/index.php?rid=1079290&amp;cid=s_33309_15_f&amp;fid=33309&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj68525wq87781322%2F</link>
            <description>We describe the sequential development of Cushing’s disease, apoplexy and aggressive pituitary
 tumor in the same patient. A 31-year old male presented with eutopic ACTH dependent Cushing’s syndrome which failed initial
 pituitary surgery. He underwent subsequent bilateral adrenalectomy for control of hypercortisolism. An episode of pituitary
 apoplexy then occurred which was followed by the development of a null-cell pituitary tumor. This second tumor exhibited an
 aggressive behavior with invasion into the surrounding structures and systemic spread clinically. This case provides important
 evidence for the hypotheses of the pathogenesis of aggressive pituitary tumors which could have arisen from surviving adenoma
 cells following apoplexy or as a de novo development of pituitary carc...</description>
            <author>Pituitary</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1079290</comments>
            <pubDate>Thu, 06 Dec 2007 16:30:40 +0100</pubDate>
            <guid isPermaLink="false">1079290</guid>        </item>
    </channel>
</rss>
